Document:

EXHIBIT 10.9  

THIS WARRANT AND THE SHARES OF COMMON STOCK
ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY STATE SECURITIES LAWS AND MAY
NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED UNDER THE
SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR ORTEC
INTERNATIONAL, INC. SHALL HAVE RECEIVED AN OPINION OF ITS COUNSEL THAT
REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS
OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.

WARRANT TO PURCHASE

SHARES OF COMMON STOCK

OF

ORTEC
INTERNATIONAL, INC.

	
 

	
 

	
 

	
No.: W-SK1

	
 

	
Number of Shares: 2,051,798

	
Date of
  Issuance: June 18, 2007

	
 

	
 

          FOR
VALUE RECEIVED, subject to the provisions hereinafter set forth, the
undersigned, Ortec International, Inc., a Delaware corporation (together with
its successors and assigns, the “Issuer”), hereby certifies that Steven
Katz or his registered assigns is entitled to subscribe for and purchase,
during the period specified in this Warrant, up to two million fifty one
thousand seven hundred ninety eight (2,051,798) shares (subject to adjustment
as hereinafter provided) of the duly authorized, validly issued, fully paid and
non-assessable Common Stock of the Issuer, at an exercise price per share equal
to the Warrant Price then in effect, subject, however, to the provisions and
upon the terms and conditions hereinafter set forth. Capitalized terms used in
this Warrant and not otherwise defined herein shall have the respective
meanings specified in Section 9 hereof.

          1.
Term. The right to subscribe for and purchase shares of Warrant Stock
represented hereby shall commence on June 18, 2007 and shall expire at 5:00
p.m., eastern time, on June 17, 2012 (such period being the “Term”).

          2.
Method of Exercise Payment; Issuance of New Warrant; Transfer and Exchange.

          (a)
Time of Exercise. The purchase rights represented by this Warrant may be
exercised in whole or in part at any time and from time to time during the
Term.

          (b)
Method of Exercise. The Holder hereof may exercise this Warrant, in
whole or in part, by the surrender of this Warrant (with the exercise form
attached hereto duly executed) at the principal office of the Issuer, and by
the payment to the Issuer of an amount of consideration

therefor equal
to the Warrant Price in effect on the date of such exercise multiplied by the
number of shares of Warrant Stock with respect to which this Warrant is then
being exercised, payable at such Holder’s election (i) by certified or official
bank check or by wire transfer to an account designated by the Issuer, (ii) by
“cashless exercise” in accordance with the provisions of subsection (c) of this
Section 2, but only when a registration statement under the Securities Act
providing for resale of all of the Warrant Stock is not then in effect and in
any event not earlier than after the earlier date of (A) June 18, 2008 or (B)
120 days after the Holder’s written demand upon the Issuer to file a
registration statement under the Securities Act registering and qualifying the
Warrant Stock for sale in the public securities markets, which written demand
the Holder may not make until the earlier of (a) March 18, 2008 or (b) six months
after the effective date of the Initial Registration Statement, or (iii) by a
combination of the foregoing methods of payment selected by the Holder of this
Warrant.

          (c)
Cashless Exercise. Notwithstanding any provisions herein to the contrary
but only during the period provided in clause (ii) of Section 2(b)
hereof, if (i) the Per Share Market Value of one share of Common Stock is
greater than the Warrant Price (at the date of calculation as set forth below)
and (ii) a registration statement under the Securities Act providing for the
resale of all of the Warrant Stock is not then in effect, in lieu of exercising
this Warrant by payment of cash, the Holder may exercise this Warrant by a
cashless exercise and shall receive the number of shares of Common Stock equal
to an amount (as determined below) by surrender of this Warrant at the
principal office of the Issuer together with the properly endorsed Notice of
Exercise in which event the Issuer shall issue to the Holder a number of shares
of Common Stock computed using the following formula:

	
 

	
 

	
 

	
 

	
X = Y - 

	
(A)(Y)

	
 

	
 

	

	
 

	
 

	
     B

	
 

	
 

	
 

	
Where

	
X =

	
the number
  of shares of Common Stock to be issued to the Holder.

	
 

	
 

	
 

	
 

	
Y =

	
the number
  of shares of Common Stock purchasable upon exercise of all of the Warrant or,
  if only a portion of the Warrant is being exercised, the portion of the
  Warrant being exercised.

	
 

	
 

	
 

	
 

	
A =

	
the Warrant
  Price.

	
 

	
 

	
 

	
 

	
B =

	
the Per
  Share Market Value of one share of Common Stock.

          (d)
Issuance of Stock Certificates. In the event of any exercise of the
rights represented by this Warrant in accordance with and subject to the terms
and conditions hereof, (i) certificates for the shares of Warrant Stock so
purchased shall be dated the date of such exercise and delivered to the Holder hereof
within a reasonable time, not exceeding three (3) Trading Days after such
exercise or, at the request of the Holder, issued and delivered to the
Depository Trust Company (“DTC”) account on the Holder’s behalf via the
Deposit Withdrawal Agent Commission System (“DWAC”) within a reasonable
time, not exceeding three (3) Trading Days

-2-

after such
exercise, and the Holder hereof shall be deemed for all purposes to be the
Holder of the shares of Warrant Stock so purchased as of the date of such
exercise and (ii) unless this Warrant has expired, a new Warrant representing
the number of shares of Warrant Stock, if any, with respect to which this
Warrant shall not then have been exercised (less any amount thereof which shall
have been canceled in payment or partial payment of the Warrant Price as
hereinabove provided) shall also be issued to the Holder hereof at the Issuer’s
expense within such time.

          (e)
Transferability of Warrant. Subject to Section 2(g), this Warrant may be
transferred by a Holder without the consent of the Issuer. If transferred
pursuant to this paragraph, this Warrant may be transferred on the books of the
Issuer by the Holder hereof in person or by the Holder’s duly authorized
attorney, upon surrender of this Warrant at the principal office of the Issuer,
properly endorsed (by the Holder executing an assignment in the form attached
hereto) and upon payment of any necessary transfer tax or other governmental
charge imposed upon such transfer. This Warrant is exchangeable at the principal
office of the Issuer for Warrants for the purchase of the same aggregate number
of shares of Warrant Stock, each new Warrant to represent the right to purchase
such number of shares of Warrant Stock as the Holder hereof shall designate at
the time of such exchange. All Warrants issued on transfers or exchanges shall
be dated the Original Issue Date and shall be identical with this Warrant
except as to the number of shares of Warrant Stock issuable pursuant hereto.

          (f)
Continuing Rights of Holder. The Issuer will, at the time of or at any
time after each exercise of this Warrant, upon the request of the Holder
hereof, acknowledge in writing the extent, if any, of its continuing obligation
to afford to such Holder all rights to which such Holder shall continue to be
entitled after such exercise in accordance with the terms of this Warrant, provided
that if any such Holder shall fail to make any such request, the failure shall
not affect the continuing obligation of the Issuer to afford such rights to
such Holder.

          (g)
Compliance with Securities Laws.

	
 

	
 

	
 

	
          (i)
  The Holder of this Warrant, by acceptance hereof, acknowledges that this
  Warrant and the shares of Warrant Stock to be issued upon exercise hereof are
  being acquired solely for the Holder’s own account and not as a nominee for
  any other party, and for investment, and that the Holder will not offer, sell
  or otherwise dispose of this Warrant or any shares of Warrant Stock to be
  issued upon exercise hereof except pursuant to an effective registration
  statement, or an exemption from registration, under the Securities Act and
  any applicable state securities laws.

	
 

	
 

	
 

	
          (ii)
  Except as provided in paragraph (iii) below, this Warrant and all
  certificates representing shares of Warrant Stock issued upon exercise hereof
  shall be stamped or imprinted with a legend in substantially the following
  form:

	
 

	
 

	
 

	
 

	
THIS WARRANT
  AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN 

	
 

-3-

	
 

	
 

	
 

	
 

	
REGISTERED
  UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR ANY
  STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED
  OF UNLESS REGISTERED UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE
  SECURITIES LAWS OR ORTEC INTERNATIONAL, INC. SHALL HAVE RECEIVED AN OPINION
  OF ITS COUNSEL THAT REGISTRATION OF SUCH SECURITIES UNDER THE SECURITIES ACT
  AND UNDER THE PROVISIONS OF APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED.

	
 

	
 

	
 

	
 

	
          (iii)
  The restrictions imposed by this subsection (g) upon the transfer of this
  Warrant or the shares of Warrant Stock to be purchased upon exercise hereof
  shall terminate (A) when such securities shall have been resold pursuant to
  an effective registration statement under the Securities Act, (B) upon the
  Issuer’s receipt of an opinion of counsel, in form and substance reasonably
  satisfactory to the Issuer, addressed to the Issuer to the effect that such
  restrictions are no longer required to ensure compliance with the Securities
  Act and state securities laws or (C) upon the Issuer’s receipt of other
  evidence reasonably satisfactory to the Issuer that such registration and
  qualification under the Securities Act and state securities laws are not
  required. Whenever such restrictions shall cease and terminate as to any such
  securities, the Holder thereof shall be entitled to receive from the Issuer
  (or its transfer agent and registrar), without expense (other than applicable
  transfer taxes, if any), new Warrants (or, in the case of shares of Warrant
  Stock, new stock certificates) of like tenor not bearing the applicable
  legend required by paragraph (ii) above relating to the Securities Act and
  state securities laws.

          (h) Buy In. 

                    In
addition to any other rights available to the Holder, if the Issuer fails to
cause its transfer agent to transmit to the Holder a certificate or
certificates representing the Warrant Stock pursuant to an exercise on or
before the Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) shares of
Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant
Stock which the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Issuer shall (1) pay in cash to the Holder the amount by which (x) the
Holder’s total purchase price (including brokerage commissions, if any) for the
shares of Common Stock so purchased exceeds (y) the amount obtained by
multiplying (A) the number of shares of Warrant Stock that the Issuer was
required to deliver to the Holder in connection with the exercise at issue
times, (B) the price at which the sell order giving rise to such purchase
obligation was executed, and (2) at the option of the Holder, either reinstate
the portion of the Warrant and equivalent number of shares of Warrant Stock for
which such exercise was not honored or deliver to the Holder the number of
shares of Common Stock that would have been issued had the Issuer timely
complied with its

-4-

exercise and
delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect
to an attempted exercise of shares of Common Stock with an aggregate sale price
giving rise to such purchase obligation of $10,000, under clause (1) of the
immediately preceding sentence the Issuer shall be required to pay the Holder
$1,000. The Holder shall provide the Issuer written notice indicating the
amounts payable to the Holder in respect of the Buy-In, together with
applicable confirmations and other evidence reasonably requested by the Issuer.
Nothing herein shall limit a Holder’s right to pursue any other remedies
available to it hereunder, at law or in equity including, without limitation, a
decree of specific performance and/or injunctive relief with respect to the
Issuer’s failure to timely deliver certificates representing shares of Common
Stock upon exercise of this Warrant as required pursuant to the terms hereof.

          3.
Stock Fully Paid; Reservation and Listing of Shares; Covenants.

          (a)
Stock Fully Paid. The Issuer represents, warrants, covenants and agrees
that all shares of Warrant Stock which may be issued upon the exercise of this
Warrant or otherwise hereunder will, upon issuance, be duly authorized, validly
issued, fully paid and non-assessable and free from all taxes, liens and
charges created by or through Issuer. The Issuer further covenants and agrees
that during the period within which this Warrant may be exercised, the Issuer
will at all times have authorized and reserved for the purpose of the issue
upon exercise of this Warrant a number of shares of Common Stock equal to at
least 120% of the aggregate number of shares of Common Stock exercisable
hereunder to provide for the exercise of this Warrant (without regard to
limitations or exercisability set forth in Section 8).

          (b)
Reservation. If any shares of Common Stock required to be reserved for
issuance upon exercise of this Warrant or as otherwise provided hereunder
require registration or qualification with any governmental authority under any
federal or state law before such shares may be so issued, the Issuer will in
good faith use its best efforts as expeditiously as possible at its expense to
cause such shares to be duly registered or qualified. If the Issuer shall list
any shares of Common Stock on any securities exchange or market it will, at its
expense, list thereon, maintain and increase when necessary such listing, of,
all shares of Warrant Stock from time to time issued upon exercise of this
Warrant or as otherwise provided hereunder, and, to the extent permissible
under the applicable securities exchange’s rules, all unissued shares of
Warrant Stock which are at any time issuable hereunder, so long as any shares
of Common Stock shall be so listed. The Issuer will also so list on each
securities exchange or market, and will maintain such listing of, any other
securities which the Holder of this Warrant shall be entitled to receive upon
the exercise of this Warrant if at the time any securities of the same class
shall be listed on such securities exchange or market by the Issuer.

          (c)
Covenants. The Issuer shall not by any action including, without
limitation, amending the Certificate of Incorporation or the by-laws of the
Issuer, or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other action, avoid or
seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all
such terms and in the 

-5-

taking of all
such actions as may be necessary or appropriate to protect the rights of the
Holder hereof against dilution (to the extent specifically provided herein) or
impairment. Without limiting the generality of the foregoing, the Issuer will
(i) not permit the par value, if any, of its Common Stock to exceed the then
effective Warrant Price, (ii) not amend or modify any provision of the
Certificate of Incorporation or by-laws of the Issuer in any manner that would
adversely affect the rights of the Holders of the Warrants, (iii) take all such
action as may be reasonably necessary in order that the Issuer may validly and
legally issue fully paid and nonassessable shares of Common Stock, free and
clear of any liens, claims, encumbrances and restrictions (other than as
provided herein) upon the exercise of this Warrant, and (iv) use its best
efforts to obtain all such authorizations, exemptions or consents from any
public regulatory body having jurisdiction thereof as may be reasonably
necessary to enable the Issuer to perform its obligations under this Warrant.

          (d)
Loss, Theft, Destruction of Warrants. Upon receipt of evidence satisfactory
to the Issuer of the ownership of and the loss, theft, destruction or
mutilation of any Warrant and, in the case of any such loss, theft or
destruction, upon receipt of indemnity or security satisfactory to the Issuer
or, in the case of any such mutilation, upon surrender and cancellation of such
Warrant, the Issuer will make and deliver, in lieu of such lost, stolen,
destroyed or mutilated Warrant, a new Warrant of like tenor and representing
the right to purchase the same number of shares of Common Stock.

          4.
Adjustment of Warrant Price and Warrant Share Number. The number of
shares of Common Stock for which this Warrant is exercisable, and the price at
which such shares may be purchased upon exercise of this Warrant, shall be
subject to adjustment from time to time as set forth in this Section 4. The
Issuer shall give the Holder notice of any event described below which requires
an adjustment pursuant to this Section 4 in accordance with Section 5.
Notwithstanding any adjustment hereunder, at no time shall the Warrant Price be
greater than $0.55 per share except if it is adjusted pursuant to Section 4(b).

          (a)
Recapitalization, Reorganization, Reclassification, Consolidation, Merger or
Sale.

	
 

	
 

	
 

	
          (i)
  In case the Issuer after the Original Issue Date shall do any of the
  following (each, a “Triggering Event”): (a) consolidate with or merge
  into any other Person and the Issuer shall not be the continuing or surviving
  corporation of such consolidation or merger, or (b) permit any other Person
  to consolidate with or merge into the Issuer and the Issuer shall be the
  continuing or surviving Person but, in connection with such consolidation or
  merger, any Capital Stock of the Issuer shall be changed into or exchanged
  for Securities of any other Person or cash or any other property, or (c)
  transfer all or substantially all of its properties or assets to any other
  Person, or (d) effect a capital reorganization or reclassification of its
  Capital Stock, then, and in the case of each such Triggering Event, proper
  provision shall be made so that, upon the basis and the terms and in the
  manner provided in this Warrant, the Holder of this Warrant shall be entitled
  upon the exercise hereof at any time after the consummation of such Triggering
  Event, to the extent this Warrant is not exercised prior to such Triggering
  Event, to 

-6-

	
 

	
 

	
 

	
receive at
  the Warrant Price in effect at the time immediately prior to the consummation
  of such Triggering Event in lieu of the Common Stock issuable upon such
  exercise of this Warrant prior to such Triggering Event, the Securities, cash
  and property to which such Holder would have been entitled upon the
  consummation of such Triggering Event if such Holder had exercised the rights
  represented by this Warrant immediately prior thereto (including the right to
  elect the type of consideration, if applicable), subject to adjustments
  (subsequent to such corporate action) as nearly equivalent as possible to the
  adjustments provided for elsewhere in this Section 4. In the event that the
  surviving entity in any such Triggering Event is not a public company under
  the Securities Exchange Act of 1934, the common equity securities of which
  are traded or quoted on a national securities exchange or the OTC Bulletin
  Board (a “Qualifying Entity”), then the Holder, at its option, shall be
  permitted to require that the Company pay to the Holder an amount equal to
  the Black-Scholes value of this Warrant.

	
 

	
 

	
 

	
          (ii)
  Notwithstanding anything contained in this Warrant to the contrary and so
  long as the surviving entity is a Qualifying Entity, the Issuer will not be
  deemed to have effected any Triggering Event if, prior to the consummation
  thereof, each Person (other than the Issuer) which may be required to deliver
  any Securities, cash or property upon the exercise of this Warrant as
  provided herein shall assume, by written instrument delivered to the Holder
  of this Warrant and reasonably satisfactory to the Holder, (A) the
  obligations of the Issuer under this Warrant (and if the Issuer shall survive
  the consummation of such Triggering Event, such assumption shall be in
  addition to, and shall not release the Issuer from, any continuing
  obligations of the Issuer under this Warrant) and (B) the obligation to
  deliver to such Holder such shares of Securities, cash or property as, in
  accordance with the foregoing provisions of this subsection (a), such Holder
  shall be entitled to receive, and such Person shall have similarly delivered
  to such Holder an opinion of counsel for such Person stating that this
  Warrant shall thereafter continue in full force and effect and the terms
  hereof (including, without limitation, all of the provisions of this
  subsection (a)) shall be applicable to the Securities, cash or property which
  such Person may be required to deliver upon any exercise of this Warrant or
  the exercise of any rights pursuant hereto. 

	
 

	
 

	
 

	
(b) Stock
  Dividends, Subdivisions and Combinations. If at any time the Issuer
  shall:

	
 

	
 

	
 

	
          (i)
  set a record date or take a record of the holders of its Common Stock for the
  purpose of entitling them to receive a dividend payable in, or other
  distribution of, Additional Shares of Common Stock, 

	
 

	
 

	
 

	
          (ii)
  subdivide its outstanding shares of Common Stock into a larger number of shares
  of Common Stock, or

	
 

	
 

	
 

	
          (iii)
  combine its outstanding shares of Common Stock into a smaller number of
  shares of Common Stock,

-7-

then (1) the
number of shares of Common Stock for which this Warrant is exercisable
immediately after the occurrence of any such event shall be adjusted to equal
the number of shares of Common Stock which a record holder of the same number
of shares of Common Stock for which this Warrant is exercisable immediately
prior to the occurrence of such event would own or be entitled to receive after
the happening of such event, and (2) the Warrant Price then in effect shall be
adjusted to equal (A) the Warrant Price then in effect multiplied by the number
of shares of Common Stock for which this Warrant is exercisable immediately
prior to the adjustment divided by (B) the number of shares of Common Stock for
which this Warrant is exercisable immediately after such adjustment.

          (c)
Certain Other Distributions. If at any time the Issuer shall set a
record date or take a record of the holders of its Common Stock for the purpose
of entitling them to receive any dividend or other distribution of:

	
 

	
 

	
 

	
          (i)
  cash (other than a cash dividend payable out of earnings or earned surplus
  legally available for the payment of dividends under the laws of the
  jurisdiction of incorporation of the Issuer),

	
 

	
 

	
 

	
          (ii)
  any evidences of its indebtedness, any shares of stock of any class or any
  other securities or property of any nature whatsoever (other than cash,
  Common Stock Equivalents, Additional Shares of Common Stock or Permitted
  Issuances), or

	
 

	
 

	
 

	
          (iii)
  any warrants or other rights to subscribe for or purchase any evidences of
  its indebtedness, any shares of stock of any class or any other securities or
  property of any nature whatsoever (other than cash, Common Stock Equivalents,
  Additional Shares of Common Stock or Permitted Issuances),

then (1) the
number of shares of Common Stock for which this Warrant is exercisable shall be
adjusted to equal the product of the number of shares of Common Stock for which
this Warrant is exercisable immediately prior to such adjustment multiplied by
a fraction (A) the numerator of which shall be the Per Share Market Value of
Common Stock at the date of taking such record and (B) the denominator of which
shall be such Per Share Market Value minus the amount allocable to one share of
Common Stock of any such cash so distributable and of the fair value (as
determined in good faith by the Board of Directors of the Issuer) of any and
all such evidences of indebtedness, shares of stock, other securities or
property or warrants or other subscription or purchase rights so distributable,
and (2) the Warrant Price then in effect shall be adjusted to equal (A) the
Warrant Price then in effect multiplied by the number of shares of Common Stock
for which this Warrant is exercisable immediately prior to the adjustment
divided by (B) the number of shares of Common Stock for which this Warrant is
exercisable immediately after such adjustment. A reclassification of the Common
Stock (other than a change in par value, or from par value to no par value or
from no par value to par value) into shares of Common Stock and shares of any
other class of stock shall be deemed a distribution by the Issuer to the
holders of its Common Stock of such shares of such other class of stock within
the meaning of this Section 4(c) and, if the outstanding shares of Common Stock
shall be

-8-

changed into a
larger or smaller number of shares of Common Stock as a part of such
reclassification, such change shall be deemed a subdivision or combination, as
the case may be, of the outstanding shares of Common Stock within the meaning
of Section 4(b).

          (d)
Issuance of Additional Shares of Common Stock. 

	
 

	
 

	
 

	
 

	
          (i)
  In the event the Issuer shall at any time following the Original Issue Date
  and prior to a Release Event (as defined below) issue any Additional Shares
  of Common Stock (otherwise than as provided in the foregoing subsections (a)
  through (c) of this Section 4), at a price per share less than the Warrant
  Price then in effect or without consideration, then the Warrant Price upon
  each such issuance shall be adjusted to the price equal to the consideration
  per share paid for such Additional Shares of Common Stock. Upon and after a
  Release Event, the price shall be adjusted to the price (rounded to the
  nearest cent) determined by multiplying the Warrant Price by a fraction:

	
 

	
 

	
 

	
 

	
 

	
          (A)
  the numerator of which shall be equal to the sum of (x) the number of shares
  of Outstanding Common Stock immediately prior to the issuance of such
  Additional Shares of Common Stock plus (y) the number of shares of
  Common Stock (rounded to the nearest whole share) which the aggregate
  consideration for the total number of such Additional Shares of Common Stock
  so issued would purchase at a price per share equal to the Warrant Price then
  in effect, and

	
 

	
 

	
 

	
 

	
 

	
          (B)
  the denominator of which shall be equal to the number of shares of
  Outstanding Common Stock immediately after the issuance of such Additional
  Shares of Common Stock.

	
 

	
 

	
 

	
 

	
          (ii)
  No adjustment of the Warrant Price shall be made under paragraph (i) of
  Section 4(d) upon the issuance of any Additional Shares of Common Stock
  which are issued pursuant to the exercise or conversion of any Common Stock
  Equivalents if any such adjustment shall previously have been made upon the
  issuance of such Common Stock Equivalents, or upon the issuance of any
  warrant or other rights therefor pursuant to Sections 4(e) or 4(f), or in
  connection with any Permitted Issuances. The term “Release Event” means, with
  respect to the holder’s Warrant Stock, the date on which the Company has
  received U.S. Food and Drug Administration approval of the Company’s Pre-Market
  Application for its OrCel product for the treatment of venous leg ulcers.

          (e)
Issuance of Warrants or Other Rights. If at any time prior to a Release
Event the Issuer shall take a record of the Holders of its Common Stock for the
purpose of entitling them to receive a distribution of, or shall in any manner
(whether directly or by assumption in a merger in which the Issuer is the
surviving corporation) issue or sell any warrants or options, whether or not
immediately exercisable, and the Warrant Consideration (hereafter defined) per
share for which Common Stock is issuable upon the exercise of such warrant or
option shall be less than the Warrant Price in effect immediately prior to the
time of such issue or sale, then the Warrant

-9-

Price then in
effect immediately prior to the time of such issue or sale, shall be adjusted
to the price equal to the Warrant Consideration per share for which Common
Stock is issuable upon the exercise of such warrant or option. Upon and after a
Release Event, this right shall cease. In the event the Issuer shall at any
time following a Release Event issue any warrants or options at a price per
share less than the Warrant Price then in effect or without consideration, the
price shall be adjusted to the price (rounded to the nearest cent) determined
by multiplying the Warrant Price by a fraction: (1) the numerator of which
shall be equal to the sum of (A) the number of shares of Common Stock
outstanding immediately prior to the issuance or sale of such warrants or
options plus (B) the number of shares of Common Stock (rounded to the
nearest whole share) which the Warrant Consideration multiplied by the number
of shares of Common Stock issuable upon the exercise or conversion of all such
warrants or options, would purchase at a price per share equal to the Warrant
Price then in effect, and (2) the denominator of which shall be equal to the
number of shares of Common Stock that would be outstanding assuming the
exercise or conversion of all such warrants and options. No adjustments of the
Warrant Price then in effect shall be made upon the actual issue of such Common
Stock or of such Common Stock Equivalents upon exercise of such warrants or
other rights or upon the actual issue of such Common Stock upon such conversion
or exchange of such Common Stock Equivalents. No adjustments of the Warrant
Price shall be made under this Section 4(e) in connection with any Permitted
Issuances.

          (f)
Issuance of Common Stock Equivalents. If at any time prior to a Release
Event the Issuer shall take a record of the Holders of its Common Stock for the
purpose of entitling them to receive a distribution of, or shall in any manner
(whether directly or by assumption in a merger in which the Issuer is the
surviving corporation) issue or sell, any Common Stock Equivalents, whether or
not the rights to exchange or convert thereunder are immediately exercisable,
and the Common Stock Equivalent Consideration (hereafter defined) per share for
which Common Stock is issuable upon such conversion or exchange shall be less
than the Warrant Price in effect immediately prior to the time of such issue or
sale, or if, after any such issuance of Common Stock Equivalents, the price per
share for which Additional Shares of Common Stock may be issuable thereafter is
amended or adjusted, and such price as so amended shall be less than the
applicable Conversion Price in effect at the time of such amendment or
adjustment, then the Warrant Price then in effect immediately prior to the time
of such issue or sale, shall upon each such issuance or sale be adjusted to the
price equal to the Common Stock Equivalent Consideration per share paid for
such Common Share Equivalents. Upon and after a Release Event, this right shall
cease. In the event the Issuer shall at any time following a Release Event
issue any Common Stock Equivalents for Common Stock Equivalent Consideration
per share less than the Warrant Price then in effect or without consideration,
then the Warrant Price upon each such issuance shall be adjusted to that price
(rounded to the nearest cent) determined by multiplying the Warrant Price by a
fraction: (1) the numerator of which shall be equal to the sum of (A) the
number of shares of Common Stock outstanding immediately prior to the issuance or
sale of such Common Stock Equivalents plus (B) the number of shares of
Common Stock (rounded to the nearest whole share) which the Common Stock
Equivalent Consideration multiplied by the number of shares of Common Stock
issuable upon the exercise or conversion of all such Common Stock Equivalents,
would purchase at a price per share equal to the Warrant

-10-

Price then in
effect, and (2) the denominator of which shall be equal to the number of shares
of Common Stock that would be outstanding assuming the exercise or conversion
of all such Common Stock Equivalents. No further adjustment of the Warrant
Price then in effect shall be made under this Section 4(f) upon the issuance of
any Common Stock Equivalents which are issued pursuant to the exercise of any
warrants or other subscription or purchase rights therefor, if any such
adjustment shall previously have been made upon the issuance of such warrants
or other rights pursuant to Section 4(e). No further adjustments of the Warrant
Price then in effect shall be made upon the actual issue of such Common Stock
upon conversion or exchange of such Common Stock Equivalents. No adjustments of
the Warrant Price shall be made under this Section 4(f) in connection with any
Permitted Issuances.

          (g)
Superseding Adjustment. If, at any time after any adjustment of the
Warrant Price then in effect shall have been made pursuant to Section 4(e) or
Section 4(f) as the result of any issuance of warrants, other rights or Common
Stock Equivalents, and (i) such warrants or other rights, or the right of
conversion or exchange in such other Common Stock Equivalents, shall expire,
and all or a portion of such warrants or other rights, or the right of
conversion or exchange with respect to all or a portion of such other Common
Stock Equivalents, as the case may be shall not have been exercised, or (ii)
the consideration per share for which shares of Common Stock are issuable
pursuant to such Common Stock Equivalents, shall be increased solely by virtue
of provisions therein contained for an automatic increase in such consideration
per share upon the occurrence of a specified date or event, then for each
outstanding Warrant such previous adjustment shall be rescinded and annulled
and the Additional Shares of Common Stock which were deemed to have been issued
by virtue of the computation made in connection with the adjustment so
rescinded and annulled shall no longer be deemed to have been issued by virtue
of such computation. Upon the occurrence of an event set forth in this Section
4(g) above, there shall be a recomputation made of the effect of such Common
Stock Equivalents on the basis of: (i) treating the number of Additional Shares
of Common Stock or other property, if any, theretofore actually issued or
issuable pursuant to the previous exercise of any such warrants or other rights
or any such right of conversion or exchange, as having been issued on the date
or dates of any such exercise and for the consideration actually received and
receivable therefor, and (ii) treating any such Common Stock Equivalents which
then remain outstanding as having been granted or issued immediately after the
time of such increase of the consideration per share for which shares of Common
Stock or other property are issuable under such Common Stock Equivalents;
whereupon a new adjustment of the Warrant Price then in effect shall be made,
which new adjustment shall supersede the previous adjustment so rescinded and
annulled.

          (h)
Purchase of Common Stock by the Issuer. If the Issuer at any time while
this Warrant is outstanding shall, directly or indirectly through a Subsidiary
or otherwise, purchase, redeem or otherwise acquire any shares of Common Stock
at a price per share greater than the Per Share Market Value, then the Warrant
Price upon each such purchase, redemption or acquisition shall be adjusted to
that price determined by multiplying such Warrant Price by a fraction (i) the
numerator of which shall be the number of shares of Common Stock outstanding
immediately prior to such purchase, redemption or acquisition minus the number
of shares of Common Stock which the aggregate consideration for the total
number of such shares of

-11-

Common Stock
so purchased, redeemed or acquired would purchase at the Per Share Market
Value; and (ii) the denominator of which shall be the number of shares of
Common Stock outstanding immediately after such purchase, redemption or
acquisition. For the purposes of this subsection (h), the date as of which the
Per Share Market Price shall be computed shall be the earlier of (x) the date
on which the Issuer shall enter into a firm contract for the purchase,
redemption or acquisition of such Common Stock, or (y) the date of actual
purchase, redemption or acquisition of such Common Stock. For the purposes of
this subsection (h), a purchase, redemption or acquisition of a Common Stock
Equivalent shall be deemed to be a purchase of the underlying Common Stock, and
the computation herein required shall be made on the basis of the full
exercise, conversion or exchange of such Common Stock Equivalent on the date as
of which such computation is required hereby to be made, whether or not such
Common Stock Equivalent is actually exercisable, convertible or exchangeable on
such date.

          (i)
Other Provisions applicable to Adjustments under this Section. The
following provisions shall be applicable to the making of adjustments of the
Warrant Price then in effect provided for in this Section 4:

	
 

	
 

	
 

	
          (i)
  Computation of Consideration. To the extent that any Additional Shares
  of Common Stock or any Common Stock Equivalents (or any warrants or other
  rights therefor) shall be issued for cash consideration, the consideration
  received by the Issuer therefor shall be the amount of the cash received by
  the Issuer therefor, or, if such Additional Shares of Common Stock or Common
  Stock Equivalents are offered by the Issuer for subscription, the
  subscription price, or, if such Additional Shares of Common Stock or Common
  Stock Equivalents are sold to underwriters or dealers for public offering
  without a subscription offering, the initial public offering price (in any
  such case subtracting any amounts paid or receivable for accrued interest or
  accrued dividends and without taking into account any compensation, discounts
  or expenses paid or incurred by the Issuer for and in the underwriting of, or
  otherwise in connection with, the issuance thereof). To the extent that such
  issuance shall be for a consideration other than cash, then, except as herein
  otherwise expressly provided, the amount of such consideration shall be
  deemed to be the fair value of such consideration at the time of such
  issuance as mutually determined in good faith by the Board of Directors of
  the Issuer and the Majority Holders. The consideration for any Additional
  Shares of Common Stock issuable pursuant to any warrants or other rights to
  subscribe for or purchase the same shall be the consideration received by the
  Issuer for issuing such warrants or other rights divided by the number of
  shares of Common Stock issuable upon the exercise of such warrant or right
  plus the additional consideration payable to the Issuer upon exercise of
  such warrant or other right for one share of Common Stock (together the
  “Warrant Consideration”). The consideration for any Additional Shares of
  Common Stock issuable pursuant to the terms of any Common Stock Equivalents
  shall be the consideration received by the Issuer for issuing such Common
  Stock Equivalent, divided by the number of shares of Common Stock issuable
  upon the conversion or other exercise of such Common Stock Equivalent, plus
  the additional consideration, if any, payable to the Issuer upon the exercise
  of the right of conversion or exchange in such Common Stock

-12-

	
 

	
 

	
 

	
Equivalent
  for one share of Common Stock (together the “Common Stock Equivalent
  Consideration”). In case of the issuance at any time of any Additional Shares
  of Common Stock or Common Stock Equivalents in payment or satisfaction of any
  dividends upon any class of stock other than Common Stock, the Issuer shall
  be deemed to have received for such Additional Shares of Common Stock or
  Common Stock Equivalents a consideration equal to the amount of such dividend
  so paid or satisfied.

	
 

	
 

	
 

	
          (ii)
  No Adjustments of Number of Shares. No adjustment of the number of
  shares of Common Stock for which this Warrant shall be exercisable shall be
  made because of any adjustments of the Warrant Price pursuant to Sections
  (d), (e), (f), (g) and (h) of this Section 4.

	
 

	
 

	
 

	
          (iii)
  Fractional Interests. In computing adjustments under this Section 4,
  fractional interests in Common Stock shall be taken into account to the
  nearest one one-hundredth (1/100th) of a share.

	
 

	
 

	
 

	
          (iv)
  When Adjustment Not Required. If the Issuer shall take a record of the
  holders of its Common Stock for the purpose of entitling them to receive a
  dividend or distribution or subscription or purchase rights and shall,
  thereafter and before the distribution to stockholders thereof, legally
  abandon its plan to pay or deliver such dividend, distribution, subscription
  or purchase rights, then thereafter no adjustment shall be required by reason
  of the taking of such record and any such adjustment previously made in
  respect thereof shall be rescinded and annulled. 

          (j)
Form of Warrant after Adjustments. The form of this Warrant need not be
changed because of any adjustments in the Warrant Price or the number and kind
of securities purchasable upon exercise of this Warrant.

          (k)
Escrow of Property. If after any property becomes distributable pursuant
to this Section 4 by reason of the taking of any record of the holders of
Common Stock, but prior to the occurrence of the event for which such record is
taken, and the Holder exercises this Warrant, such property shall be held in
escrow for the Holder by the Issuer to be distributed to the Holder upon and to
the extent that the event actually takes place, upon payment of the then
current Warrant Price. Notwithstanding any other provision to the contrary
herein, if the event for which such record was taken fails to occur or is
rescinded, then such escrowed property shall be returned to the Issuer.

          5.
Notice of Adjustments. Whenever the Warrant Price or Warrant Share
Number shall be adjusted pursuant to Section 4 hereof (for purposes of this
Section 5, each an “adjustment”), the Issuer shall cause its Chief Financial
Officer to prepare and execute a certificate setting forth, in reasonable
detail, the event requiring the adjustment, the amount of the adjustment, the
method by which such adjustment was calculated (including a description of the
basis on which the Board made any determination hereunder), and the Warrant
Price and Warrant Share Number after giving effect to such adjustment, and
shall cause copies of such

-13-

certificate to
be delivered to the Holder of this Warrant promptly after each adjustment. Any
dispute between the Issuer and the Holder of this Warrant with respect to the
matters set forth in such certificate may at the option of the Holder of this
Warrant be submitted to one of the national accounting firms currently known as
the “big five” selected by the Holder, provided that the Issuer shall
have ten (10) days after receipt of notice from such Holder of its selection of
such firm to object thereto, in which case such Holder shall select another
such firm and the Issuer shall have no such right of objection. The firm
selected by the Holder of this Warrant as provided in the preceding sentence
shall be instructed to deliver a written opinion as to such matters to the
Issuer and such Holder within thirty (30) days after submission to it of such
dispute. Such opinion shall be final and binding on the parties hereto. 

          6.
Fractional Shares. No fractional shares of Warrant Stock will be issued
in connection with and exercise hereof, but in lieu of such fractional shares,
the Issuer shall at its option either (a) make a cash payment therefor equal in
amount to the product of the applicable fraction multiplied by the Per Share
Market Value then in effect or (b) issue one whole share in lieu of such
fractional share.

          7.
Intentionally Omitted. 

          8.
Certain Exercise Restrictions. Notwithstanding anything to the contrary
set forth in this Warrant, at no time may a holder of this Warrant exercise
this Warrant if the number of shares of Common Stock to be issued pursuant to
such exercise would exceed, when aggregated with all other shares of Common
Stock owned by such holder at such time, the number of shares of Common Stock which
would result in such holder beneficially owning (as determined in accordance
with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the
rules thereunder) in excess of 9.999% of all of the Common Stock outstanding at
such time; provided, however, that upon a holder of this Warrant
providing the Issuer with sixty-one (61) days notice (pursuant to Section 13
hereof) (the “Waiver Notice”) that such holder would like to waive this Section
8 with regard to any or all shares of Common Stock issuable upon exercise of
this Warrant, this Section 8 will be of no force or effect with regard to all
or a portion of the Warrant referenced in the Waiver Notice; provided, further,
that this provision shall be of no further force or effect during the sixty-one
(61) days immediately preceding the expiration of the term of this Warrant.

          9.
Definitions. For the purposes of this Warrant, the following terms have
the following meanings:

	
 

	
 

	
 

	
          “Additional
  Shares of Common Stock” means all shares of Common Stock issued by the
  Issuer after the Original Issue Date, and all shares of Other Common, if any,
  issued by the Issuer after the Original Issue Date, except for Permitted
  Issuances.

	
 

	
 

	
 

	
          “Board”
  shall mean the Board of Directors of the Issuer.

-14-

	
 

	
 

	
 

	
          “Capital
  Stock” means and includes (i) any and all shares, interests,
  participations or other equivalents of or interests in (however designated)
  corporate stock, including, without limitation, shares of preferred or
  preference stock, (ii) all partnership interests (whether general or limited)
  in any Person which is a partnership, (iii) all membership interests or
  limited liability company interests in any limited liability company, and
  (iv) all equity or ownership interests in any Person of any other type.

	
 

	
 

	
 

	
          “Certificate
  of Incorporation” means the Certificate of Incorporation of the Issuer as
  in effect on the Original Issue Date, and as hereafter from time to time
  amended, modified, supplemented or restated in accordance with the terms
  hereof and thereof and pursuant to applicable law.

	
 

	
 

	
 

	
          “Common
  Stock” means the Common Stock, par value $.001 per share, of the Issuer
  and any other Capital Stock into which such stock may hereafter be changed.

	
 

	
 

	
 

	
          “Common
  Stock Equivalent” means any Convertible Security or warrant, option or
  other right to subscribe for or purchase any Additional Shares of Common
  Stock or any Convertible Security.

	
 

	
 

	
 

	
          “Common
  Stock Equivalent Consideration” has the meaning specified in Section 4
  (i) (i) hereof.

	
 

	
 

	
 

	
          “Convertible
  Securities” means evidences of Indebtedness, shares of Capital Stock or
  other Securities which are or may be at any time convertible into or
  exchangeable for Additional Shares of Common Stock. The term “Convertible
  Security” means one of the Convertible Securities.

	
 

	
 

	
 

	
          “Governmental
  Authority” means any governmental, regulatory or self-regulatory entity,
  department, body, official, authority, commission, board, agency or
  instrumentality, whether federal, state or local, and whether domestic or
  foreign.

	
 

	
 

	
 

	
          “Holders”
  mean the Persons who shall from time to time own any Warrant. The term
  “Holder” means one of the Holders.

	
 

	
 

	
 

	
          “Independent
  Appraiser” means a nationally recognized or major regional investment
  banking firm or firm of independent certified public accountants of
  recognized standing (which may be the firm that regularly examines the
  financial statements of the Issuer) that is regularly engaged in the business
  of appraising the Capital Stock or assets of corporations or other entities
  as going concerns, and which is not affiliated with either the Issuer or the
  Holder of any Warrant.

	
 

	
 

	
 

	
          “Initial
  Registration Statement” means the registration statement under the
  Securities Act which the Issuer is required to file registering and
  qualifying for sale in the 

-15-

	
 

	
 

	
 

	
public
  securities markets shares of Common Stock issuable upon conversion of the
  Issuer’s Series A Convertible Preferred Stock.

	
 

	
 

	
          “Issuer”
  means Ortec International, Inc., a Delaware corporation, and its successors. 

	
 

	
 

	
 

	
          “Majority
  Holders” means at any time the Holders of the Issuer’s Series A, Series
  M-1, Series RL and Series SK Warrants exercisable for a majority of all the
  shares of the Issuer’s common stock issuable upon exercise of all such
  warrants then outstanding.

	
 

	
 

	
 

	
          “Original
  Issue Date” means June 18, 2007.

	
 

	
 

	
 

	
            “OTC Bulletin Board” means the
  over-the-counter electronic bulletin board.

	
 

	
 

	
 

	
          “Other
  Common” means any other Capital Stock of the Issuer of any class which
  shall be authorized at any time after the date of this Warrant (other than
  Common Stock) and which shall have the right to participate in the
  distribution of earnings and assets of the Issuer without limitation as to
  amount.

	
 

	
 

	
 

	
           “Outstanding Common Stock” means, at
  any given time, the aggregate amount of outstanding shares of Common Stock,
  assuming full exercise, conversion or exchange (as applicable) of all
  options, warrants and other Securities which are convertible into or
  exercisable or exchangeable for, and any right to subscribe for, shares of
  Common Stock that are outstanding at such time.

	
 

	
 

	
 

	
          “Permitted
  Issuances” means (i) the issuance of the Warrant Stock; (ii) issuances in
  connection with strategic license agreements so long as such issuances are
  not for the purpose of raising capital; (iii) when approved by the Company’s
  Board of Directors or by a committee of the Board of Directors the majority
  of whom are independent directors, the

	
 

	
 

	
 

	
 

	
 

	
 

	
(A)

	

  issuances and/or

	
 

	
 

	
 

	
(B)

	
 grant of
  stock options or warrants to purchase shares of Common Stock, whether the
  grants of such options or warrants are made under the Company’s Employee
  Stock Option Plan or its 2006 Stock Award or any stock award and incentive
  plan, as they now exist, or hereafter adopted or otherwise so long as such
  issuances in the aggregate do not exceed ten percent (10)% of the issued and
  outstanding shares of Common Stock as of the Original Issue Date, 

	
 

	
 

	
 

	
to the
  Company’s officers, directors, employees and consultants and to suppliers of
  goods and/or services to the Company; (vi) securities issued upon the
  exercise, conversion or 

-16-

	
 

	
 

	
 

	
exchange of
  any Common Stock Equivalents outstanding on the Original Issue Date at the
  conversion price set forth therein as of the Original Issue Date; (vii)
  issuance of Series A Preferred Stock pursuant to the Purchase Agreement, or
  Common Stock issued upon conversion thereof; (viii) issuance of Series A-1
  Convertible Preferred Stock at the conversion price set forth therein as of
  the Original Issue Date and Series A-2 Convertible Preferred Stock at the
  conversion price set forth therein as of the Original Issue Date, as adjusted
  by the anti-dilution provisions in effect on the Original Issue Date, or
  Common Stock issued upon the conversion of such Series A-1 Convertible
  Preferred Stock and Series A-2 Convertible Preferred Stock; (ix) any warrants
  issued to Burnham Hill Partners, a division of Pali Capital Inc., or any
  other person or entity for services in connection with the transactions
  contemplated by the Purchase Agreement at the conversion price set forth
  therein as of the Original Issue Date, as adjusted by the anti-dilution
  provisions in effect on the Original Issue Date, and the shares of Common
  Stock issued upon exercise thereof; (x) warrants issued to Ron Lipstein and
  Steven Katz in connection with the agreements terminating their employment
  with the Company at the price set forth therein on the Issuance Date; (xi)
  issuance of Series D-2 Convertible Preferred Stock, or Common Stock issued
  upon the conversion of such Series D-2 Convertible Preferred Stock; or (xii)
  the exchange of warrants outstanding prior to the Original Issue Date for
  shares of Common Stock or the Company’s other equity securities.

	
 

	
 

	
 

	
          “Person”
  means an individual, corporation, limited liability company, partnership,
  joint stock company, trust, unincorporated organization, joint venture,
  Governmental Authority or other entity of whatever nature.

	
 

	
 

	
 

	
          “Per
  Share Market Value” means on any particular date (a) the closing bid
  price for a share of Common Stock in the over-the-counter market, as reported
  by the OTC Bulletin Board or in the National Quotation Bureau Incorporated or
  similar organization or agency succeeding to its functions of reporting
  prices) at the close of business on such date, or (b) if the Common Stock is
  not then reported by the OTC Bulletin Board or the National Quotation Bureau
  Incorporated (or similar organization or agency succeeding to its functions
  of reporting prices), then the average of the “Pink Sheet” quotes for the
  Common Stock on such date, or (c) if the Common Stock is not then publicly
  traded the fair market value of a share of Common Stock on such date as
  determined by the Board in good faith; provided, however, that
  the Majority Holders, after receipt of the determination by the Board, shall
  have the right to select, jointly with the Issuer, an Independent Appraiser,
  in which case, the fair market value shall be the determination by such
  Independent Appraiser; and provided, further that all
  determinations of the Per Share Market Value shall be appropriately adjusted
  for any stock dividends, stock splits or other similar transactions during
  the period between the date as of which such market value was required to be
  determined and the date it is finally determined. The determination of fair
  market value shall be based upon the fair market value of the Issuer
  determined on a going concern basis as between a willing buyer and a willing
  seller and taking into account all relevant factors determinative of value,
  and shall be final and 

-17-

	
 

	
 

	
 

	
binding on
  all parties. In determining the fair market value of any shares of Common
  Stock, no consideration shall be given to any restrictions on transfer of the
  Common Stock imposed by agreement or by federal or state securities laws, or
  to the existence or absence of, or any limitations on, voting rights.

	
 

	
 

	
 

	
          “Securities”
  means any debt or equity securities of the Issuer, whether now or hereafter
  authorized, any instrument convertible into or exchangeable for Securities or
  a Security, and any option, warrant or other right to purchase or acquire any
  Security. “Security” means one of the Securities.

	
 

	
 

	
 

	
          “Securities
  Act” means the Securities Act of 1933, as amended, or any similar federal
  statute then in effect.

	
 

	
 

	
 

	
          “Subsidiary”
  means any corporation at least 50% of whose outstanding Voting Stock, and a
  limited liability company at least 50% of whose membership interests, shall
  at the time be owned directly or indirectly by the Issuer or by one or more
  of its Subsidiaries.

	
 

	
 

	
 

	
          “Term”
  has the meaning specified in Section 1 hereof.

	
 

	
 

	
 

	
          “Trading
  Day” means (a) a day on which the Common Stock is traded on the OTC
  Bulletin Board, or (b) if the Common Stock is not traded on the OTC Bulletin
  Board, a day on which the Common Stock is quoted in the over-the-counter market
  as reported by the National Quotation Bureau Incorporated (or any similar
  organization or agency succeeding its functions of reporting prices); provided,
  however, that in the event that the Common Stock is not listed or
  quoted as set forth in (a) or (b) hereof, then Trading Day shall mean any day
  except Saturday, Sunday and any day which shall be a legal holiday or a day
  on which banking institutions in the State of New York are authorized or
  required by law or other government action to close.

	
 

	
 

	
 

	
          “Voting
  Stock” means, as applied to the Capital Stock of any corporation, Capital
  Stock of any class or classes (however designated) having ordinary voting
  power for the election of a majority of the members of the Board of Directors
  (or other governing body) of such corporation, other than Capital Stock
  having such power only by reason of the happening of a contingency.

	
 

	
 

	
 

	
          “Warrant Consideration” has the
  meaning specified in Section 4(i)(i) hereof.

	
 

	
 

	
 

	
          “Warrant
  Price” initially means U.S. $0.55, as such price may be adjusted from
  time to time as shall result from the adjustments specified in this Warrant,
  including Section 4 hereof.

	
 

	
 

	
 

	
          “Warrant
  Share Number” means at any time the aggregate number of shares of Warrant
  Stock which may at such time be purchased upon exercise of this Warrant,
  after 

-18-

	
 

	
 

	
 

	
giving
  effect to all prior adjustments and increases to such number made or required
  to be made under the terms hereof.

	
 

	
 

	
 

	
          “Warrant
  Stock” means Common Stock issuable upon exercise of any Warrant or
  Warrants or otherwise issuable pursuant to any Warrant or Warrants.

          10.
Other Notices. In case at any time:

	
 

	
 

	
 

	
 

	
(A)

	
the Issuer
  shall make any distributions to the holders of Common Stock; or

	
 

	
 

	
 

	
 

	
(B)

	
the Issuer
  shall authorize the granting to all holders of its Common Stock of rights to
  subscribe for or purchase any shares of Capital Stock of any class or of any
  Common Stock Equivalents or other rights; or

	
 

	
 

	
 

	
 

	
(C)

	
there shall
  be any reclassification of the Capital Stock of the Issuer; or

	
 

	
 

	
 

	
 

	
(D)

	
there shall
  be any capital reorganization by the Issuer; or

	
 

	
 

	
 

	
 

	
(E)

	
there shall
  be any (i) consolidation or merger involving the Issuer or (ii) sale,
  transfer or other disposition of all or substantially all of the Issuer’s
  property, assets or business (except a merger or other reorganization in
  which the Issuer shall be the surviving corporation and its shares of Capital
  Stock shall continue to be outstanding and unchanged and except a
  consolidation, merger, sale, transfer or other disposition involving a
  wholly-owned Subsidiary); or

	
 

	
 

	
 

	
 

	
(F)

	
there shall
  be a voluntary or involuntary dissolution, liquidation or winding-up of the
  Issuer or any partial liquidation of the Issuer or distribution to holders of
  Common Stock;

then, in each
of such cases, the Issuer shall give written notice to the Holder of the date
on which (i) the books of the Issuer shall close or a record shall be taken for
such dividend, distribution or subscription rights or (ii) such reorganization,
reclassification, consolidation, merger, disposition, dissolution, liquidation
or winding-up, as the case may be, shall take place. Such notice also shall
specify the date as of which the holders of Common Stock of record shall
participate in such dividend, distribution or subscription rights, or shall be
entitled to exchange their certificates for Common Stock for securities or
other property deliverable upon such reorganization, reclassification,
consolidation, merger, disposition, dissolution, liquidation or winding-up, as
the case may be. Such notice shall be given at least twenty (20) days prior to
the

-19-

action in
question and not less than twenty (20) days prior to the record date or the
date on which the Issuer’s transfer books are closed in respect thereto. The
Holder shall have the right to send two (2) representatives selected by it to
each meeting, who shall be permitted to attend, but not vote at, such meeting
and any adjournments thereof. This Warrant entitles the Holder to receive
copies of all financial and other information distributed or required to be
distributed to the holders of the Common Stock.

          11.
Amendment and Waiver. Any term, covenant, agreement or condition in this
Warrant may be amended, or compliance therewith may be waived (either generally
or in a particular instance and either retroactively or prospectively), only by
a written instrument or written instruments executed by the Issuer and the
Majority Holders; provided, however, that such amendment or
waiver shall (a) not reduce the Warrant Share Number, increase the Warrant
Price, shorten the period during which this Warrant may be exercised or modify
any provision of this Section 11 without the consent of the Holder of this
Warrant or (b) apply equally to all of the Issuer’s Series A, Series M-1,
Series RL and Series SK Warrants then outstanding.

          12.
Governing Law. THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO
PRINCIPLES OF CONFLICTS OF LAW.

          13. Notices.
Any and all notices or other communications or deliveries required or permitted
to be provided hereunder shall be in writing and shall be deemed given and
effective on the earlier of (i) the date of transmission, if such notice or
communication is delivered via facsimile at the facsimile telephone number
specified for notice prior to 5:00 p.m., eastern time, on a Trading Day, (ii)
the Trading Day after the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile telephone number specified for
notice later than 5:00 p.m., eastern time, on any date and earlier than 11:59
p.m., eastern time, on such date, (iii) the Trading Day following the date of
mailing, if sent by nationally recognized overnight courier service or (iv)
actual receipt by the party to whom such notice is required to be given. The
addresses for such communications shall be with respect to the Holder of this
Warrant or of Warrant Stock issued pursuant hereto, addressed to such Holder at
its last known address or facsimile number appearing on the books of the Issuer
maintained for such purposes, or with respect to the Issuer, addressed to:

	
 

	
 

	
 

	
Ortec International, Inc.

  3960 Broadway

  New York, NY 10032

  Attention: Chief Financial Officer

  Tel. No.: (212) 740-6999

  Fax No.: (212) 740-2570

	
 

	
 

	
 

	
with a copy
  to:

	
 

	
 

	
 

	
Feder
  Kaszovitz Isaacson Weber Skala Bass & Rhine, LLP

-20-

	
 

	
 

	
 

	
750
  Lexington Avenue

  New York, New York 10022

  Attention: Gabriel Kaszovitz, Esq. 

  Tel. No.: (212) 888-8200 

  Fax No.: (212) 888-7776

Any party
hereto may from time to time change its address for notices by giving at least
ten (10) days written notice of such changed address to the other party hereto.

          14.
Warrant Agent. The Issuer may, by written notice to each Holder of this
Warrant, appoint an agent having an office in New York, New York for the
purpose of issuing shares of Warrant Stock on the exercise of this Warrant
pursuant to subsection (b) of Section 2 hereof, exchanging this Warrant
pursuant to subsection (d) of Section 2 hereof or replacing this Warrant
pursuant to subsection (d) of Section 3 hereof, or any of the foregoing, and
thereafter any such issuance, exchange or replacement, as the case may be,
shall be made at such office by such agent.

          15.
Remedies. The Issuer stipulates that the remedies at law of the Holder
of this Warrant in the event of any default or threatened default by the Issuer
in the performance of or compliance with any of the terms of this Warrant are
not and will not be adequate and that, to the fullest extent permitted by law,
such terms may be specifically enforced by a decree for the specific
performance of any agreement contained herein or by an injunction against a
violation of any of the terms hereof or otherwise.

          16.
Successors and Assigns. This Warrant and the rights evidenced hereby
shall inure to the benefit of and be binding upon the successors and assigns of
the Issuer, the Holder hereof and (to the extent provided herein) the Holders
of Warrant Stock issued pursuant hereto, and shall be enforceable by any such
Holder or Holder of Warrant Stock.

          17.
Modification and Severability. If, in any action before any court or
agency legally empowered to enforce any provision contained herein, any
provision hereof is found to be unenforceable, then such provision shall be
deemed modified to the extent necessary to make it enforceable by such court or
agency. If any such provision is not enforceable as set forth in the preceding
sentence, the unenforceability of such provision shall not affect the other
provisions of this Warrant, but this Warrant shall be construed as if such
unenforceable provision had never been contained herein.

          18.
Headings. The headings of the Sections of this Warrant are for
convenience of reference only and shall not, for any purpose, be deemed a part
of this Warrant.

          IN
WITNESS WHEREOF, the Issuer has executed this Warrant as of the day and year
first above written.

-21-

	
 

	
 

	
 

	
 

	
ORTEC INTERNATIONAL, INC.

	
 

	
 

	
 

	
By:

	
 /s/ Alan
  Schoenbart

	
 

	
 

	

	
 

	
 

	
Name:
  Alan W. Schoenbart

	
 

	
 

	
Title: Chief Financial Officer

-22-

WARRANT

EXERCISE FORM

ORTEC
INTERNATIONAL, INC.

The undersigned
_______________, pursuant to the provisions of the within Warrant, hereby
elects to purchase _____ shares of Common Stock of Ortec International, Inc.
covered by the within Warrant.

	
 

	
 

	
 

	
 

	
 

	
Dated:

	
 

	
Signature 

	
 

	
 

	
 

	

	
 

	
 

	

	
 

	
 

	
Address 

	
 

	
 

	
 

	
 

	
 

	
 

	

	
 

	
 

	
 

	
 

	

Number of shares of Common
Stock beneficially owned or deemed beneficially owned by the Holder on the date
of Exercise: _________________________

The undersigned is an
“accredited investor” as defined in Regulation D under the Securities Act of
1933, as amended.

The undersigned intends that
payment of the Warrant Price shall be made as (check one): 

                    Cash
Exercise_______ 

                    Cashless
Exercise_______

If the Holder has elected a
Cash Exercise, the Holder shall pay the sum of $________ by certified or
official bank check (or via wire transfer) to the Issuer in accordance with the
terms of the Warrant. 

If the Holder has elected a
Cashless Exercise, a certificate shall be issued to the Holder for the number
of shares equal to the whole number portion of the product of the calculation
set forth below, which is ________.

          X
= Y - (A)(Y)

                           B

 Where: 

The number of shares of
Common Stock to be issued to the Holder __________________(“X”).

The number of shares of
Common Stock purchasable upon exercise of all of the Warrant or, if only a
portion of the Warrant is being exercised, the portion of the Warrant being
exercised ___________________________ (“Y”). 

The Warrant Price
______________ (“A”). 

The Per Share Market Value
of one share of Common Stock _______________________ (“B”).

-23-

ASSIGNMENT

FOR VALUE RECEIVED,
_________________ hereby sells, assigns and transfers unto __________________
the within Warrant and all rights evidenced thereby and does irrevocably
constitute and appoint _____________, attorney, to transfer the said Warrant on
the books of the within named corporation.

	
 

	
 

	
 

	
 

	
 

	
Dated:

	
 

	
Signature 

	
 

	
 

	
 

	

	
 

	
 

	

	
 

	
 

	
Address 

	
 

	
 

	
 

	
 

	
 

	
 

	

	
 

	
 

	
 

	
 

	

PARTIAL ASSIGNMENT

FOR VALUE RECEIVED,
_________________ hereby sells, assigns and transfers unto __________________
the right to purchase _________ shares of Warrant Stock evidenced by the within
Warrant together with all rights therein, and does irrevocably constitute and
appoint ___________________, attorney, to transfer that part of the said
Warrant on the books of the within named corporation.

	
 

	
 

	
 

	
 

	
 

	
Dated:

	
 

	
Signature 

	
 

	
 

	
 

	

	
 

	
 

	

	
 

	
 

	
Address 

	
 

	
 

	
 

	
 

	
 

	
 

	

	
 

	
 

	
 

	
 

	

FOR USE BY THE ISSUER ONLY:

This Warrant No. W-___ canceled
(or transferred or exchanged) this _____ day of ___________, _____, shares of
Common Stock issued therefor in the name of _______________, Warrant No.
W-_____ issued for ____ shares of Common Stock in the name of _______________.

-24-Exhibit 4.11

	
 

	

QUEST DIAGNOSTICS INCORPORATED,

as Issuer

THE SUBSIDIARY GUARANTORS NAMED HEREIN,

as Subsidiary Guarantors

and

THE BANK OF NEW YORK,

as Trustee

Tenth Supplemental Indenture

Dated as of June 22, 2007

	
 

	

TABLE OF CONTENTS

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
Page

	
ARTICLE I. DEFINITIONS

	
 

	
7

	
 

	
 

	
 

	
 

	
SECTION 1.1. Certain Terms Defined in the
  Indenture

	
 

	
7

	
 

	
 

	
 

	
 

	
 

	
SECTION 1.2. Definitions

	
 

	
7

	
 

	
 

	
 

	
 

	
ARTICLE II. FORM AND TERMS OF THE NOTES

	
 

	
19

	
 

	
 

	
 

	
 

	
 

	
SECTION 2.1. Form and Dating

	
 

	
19

	
 

	
 

	
 

	
 

	
 

	
SECTION 2.2. Terms of the Notes

	
 

	
22

	
 

	
 

	
 

	
 

	
 

	
SECTION 2.3 Application of the Terms of the
  Second Supplemental Indenture

	
 

	
22

	
 

	
 

	
 

	
 

	
 

	
SECTION 2.4. Application of the Article of
  the Indenture Regarding Guarantees

	
 

	
22

	
 

	
 

	
 

	
 

	
 

	
SECTION 2.5. Application of the Article of
  the Indenture Regarding Redemption of Securities

	
 

	
22

	
 

	
 

	
 

	
 

	
 

	
SECTION 2.6. Application of the Article of
  the Indenture Relating to a Sinking Fund

	
 

	
22

	
 

	
 

	
 

	
 

	
 

	
SECTION 2.7. Additional Events of Default

	
 

	
22

	
 

	
 

	
 

	
 

	
 

	
SECTION 2.8. Application of the Article of
  the Indenture Regarding Defeasance and Covenant Defeasance

	
 

	
22

	
 

	
 

	
 

	
 

	
 

	
SECTION 2.9. Application of the Article of
  the Indenture Regarding Repayment at the Option of Holders

	
 

	
22

	
 

	
 

	
 

	
 

	
 

	
SECTION 2.10. Limitation on Restricted
  Payments to Certain Non-Guarantor Subsidiaries

	
 

	
22

	
 

	
 

	
 

	
 

	
 

	
SECTION 2.11. Limitations on Subsidiary
  Indebtedness and Preferred Stock

	
 

	
22

	
 

	
 

	
 

	
 

	
 

	
SECTION 2.12. Repurchase of Notes Upon a
  Change of Control

	
 

	
22

	
 

	
 

	
 

	
 

	
ARTICLE III. MISCELLANEOUS

	
 

	
22

	
 

	
 

	
 

	
 

	
SECTION 3.1. Governing Law

	
 

	
22

	
 

	
 

	
 

	
 

	
 

	
SECTION 3.2. Separability

	
 

	
22

	
 

	
 

	
 

	
 

	
 

	
SECTION 3.3. Counterparts

	
 

	
22

	
 

	
 

	
 

	
 

	
 

	
SECTION 3.4. Ratification

	
 

	
22

	
 

	
 

	
 

	
 

1

	
 

	
 

	
 

	
 

	
 

	
SECTION 3.5. Effectiveness

	
 

	
22

	
 

	
 

	
 

	
 

	
EXHIBIT A— Form of 6.40% Senior Note due
  2017

	
 

	
A-1

	
 

	
 

	
 

	
EXHIBIT B— Form of 6.95% Senior Note due
  2037

	
 

	
B-1

	
 

	
 

	
 

	
EXHIBIT C—Form of Additional Subsidiary
  Guarantee

	
 

	
C-1

	
 

	
 

	
 

	
EXHIBIT
  D—Form of Certificate of Transfer

	
 

	
D-1

2

TENTH SUPPLEMENTAL INDENTURE

                    SUPPLEMENTAL
INDENTURE (this “Tenth Supplemental Indenture”), dated as of June 22, 2007
among QUEST DIAGNOSTICS INCORPORATED, a Delaware corporation (the “Company”),
THE BANK OF NEW YORK, a New York banking corporation, as Trustee (the
“Trustee”), and the subsidiary guarantors party hereto.

RECITALS OF THE COMPANY

                    WHEREAS,
the Company, the Trustee and the Initial Subsidiary Guarantors executed and
delivered an Indenture, dated as of June 27, 2001 (the “Base Indenture”), as
supplemented by the First Supplemental Indenture, dated as of June 27, 2001 (
the “First Supplemental Indenture”), as further supplemented by the Second
Supplemental Indenture, dated as of November 26, 2001 (the “Second Supplemental
Indenture”), as further supplemented by the Third Supplemental Indenture, dated
as of April 4, 2002 (the “Third Supplemental Indenture”), as further
supplemented by the Fourth Supplemental Indenture, dated as of March 19, 2003
(the “Fourth Supplemental Indenture”), as further supplemented by the Fifth
Supplemental Indenture, dated as of April 16, 2004 (the “Fifth Supplemental
Indenture”), as further supplemented by the Sixth Supplemental Indenture, dated
as of October 31, 2005 (the “Sixth Supplemental Indenture”), as further
supplemented by the Seventh Supplemental Indenture, dated as of November 21,
2005 (the “Seventh Supplemental Indenture”), as further supplemented by the
Eighth Supplemental Indenture, dated as of July 31, 2006 (the “Eighth
Supplemental Indenture”), as supplemented by a Ninth Supplemental Indenture,
dated as of September 30, 2006 (the “Ninth Supplemental Indenture”), and as further
supplemented by this Tenth Supplemental Indenture ( the “Tenth Supplemental
Indenture” and, collectively, the “Indenture”), to provide for the issuance by
the Company from time to time of Securities to be issued in one or mores series
as provided in the Indenture; 

                    WHEREAS,
the issuance and sale of $375,000,000 aggregate principal amount of a new
series of the Company’s 6.40% Senior Notes due July 1, 2017 guaranteed by the
Subsidiary Guarantors (the “Notes due 2017”) and $425,000,000 aggregate
principal amount of a new series of the Company’s 6.95% Senior Notes due July
1, 2037 guaranteed by the Subsidiary Guarantors (the “Notes due 2037”, and
together with the Notes due 2017, the “Notes”) have been authorized by
resolutions adopted by the Board of Directors of the Company and the Subsidiary
Guarantors;

                    WHEREAS,
the Company desires to issue and sell $800,000,000 aggregate principal amount
of the Notes on the date hereof; 

                    WHEREAS,
Sections 901(7) and 901(9) of the Indenture provide that without the consent of
the Holders of the Securities of any series issued under the Indenture, the
Company and the Subsidiary Guarantors, when authorized by a Board Resolution,
and the Trustee may enter into one or more indentures supplemental to the
Indenture to (a) establish the form or terms of Securities of any series and
any related coupons as permitted by Sections 201 and 301, including the
provisions and procedures relating to Securities convertible into or
exchangeable for any securities of any Person (including the Company) and (b)
cure any ambiguity, to correct or supplement any provision herein which may be
inconsistent with any other provision herein, or make any other provisions with
respect to matters or questions arising under the Base Indenture;

                    WHEREAS,
the Company and the Subsidiary Guarantors desire to (a) establish the form and
terms of the Notes and (b) provide whether certain Articles of the Indenture
will apply to all series of Securities, including the Notes (except as may be
provided in a Future Supplemental Indenture);

1

                    WHEREAS,
all things necessary to make this Tenth Supplemental Indenture a valid
supplement to the Indenture according to its terms and the terms of the
Indenture have been done;

                    NOW,
THEREFORE, for and in consideration of the premises stated herein and the
purchase of the Notes by the Holders thereof, the parties hereto herby enter
into this Tenth Supplemental Indenture, for the equal and proportionate benefit
of all Holders of the Notes, as follows: 

ARTICLE I.

DEFINITIONS

                    SECTION
1.1. Certain Terms
Defined in the Indenture.

                    All
capitalized terms used but not defined herein shall have the meanings ascribed
to such terms in the Indenture, as amended hereby, other than such terms as are
defined in the Second Supplemental Indenture.

                    SECTION
1.2. Definitions. 

                    Except
as may be provided in a Future Supplemental Indenture, for the benefit of the
Holders of the Notes, Section 101 of the Indenture shall be amended by adding
the following new definitions:      

          “Capital
Stock” means, with respect to any Person, any and all shares or common stock or
Preferred Stock.

          “Change
of Control” means the occurrence of any of the following: (1) the consummation
of any transaction (including, without limitation, any merger or consolidation)
the result of which is that any “person” (as that term is used in
Section 13(d)(3) of the Exchange Act)(other than the Company or one of its
subsidiaries) becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5
under the Exchange Act), directly or indirectly, of more than 50% of the Voting
Stock of the Company or other Voting Stock into which the Voting Stock of the
Company is reclassified, consolidated, exchanged or changed, measured by voting
power rather than number of shares; (2) the direct or indirect sale, transfer,
conveyance or other disposition (other than by way of merger or consolidation),
in one or more series of related transactions, of all or substantially all of
the assets of the Company and the assets of its subsidiaries, taken as a whole,
to one or more “persons” (as that term is used in Section 13(d)(3) of the
Exchange Act)(other than the Company or one of its subsidiaries); or (3) the
first day on which a majority of the members of the Board of Directors of the
Company are not Continuing Directors. Notwithstanding the foregoing, a transaction
will not be deemed to involve a Change of Control if (1) the Company becomes a
direct or indirect wholly-owned subsidiary of a holding company and (2)(A) the
direct or indirect holders of the Voting Stock of such holding company
immediately following that transaction are substantially the same as the
holders of the Voting Stock of the Company immediately prior to that
transaction or (B) immediately following that transaction no person (other than
a holding company satisfying the requirements of this sentence) is the
beneficial owner, directly or indirectly, of more than 50% of the Voting Stock
of such holding company. 

2

          “Change of Control Triggering Event”
means the occurrence of both a Change of Control and a Rating Event. 

          “Existing
Receivables Credit Facility” means the receivables-backed financing transaction
pursuant to (1) the Second Amended and Restated Receivables Sales Agreement,
dated as of April 20, 2004, among the Company and each of its direct and
indirect wholly owned Subsidiaries that is a seller thereunder, and Quest
Diagnostics Receivables Inc., as the buyer, (2) the Third Amended and Restated
Credit and Security Agreement, dated as of April 20, 2004, as amended, among
Quest Diagnostics Receivables Inc., as borrower, the Company, as initial
servicer, each of the lenders from time to time party thereto, and Wachovia
Bank, N.A., as administrative agent, and (3) the various related ancillary
documents.

          “Fitch” means Fitch Ratings. 

          “Global
Notes” means, individually and collectively, each of Global Notes,
substantially in the form of Exhibits A and B.

          “Global
Notes Legend” means the legend set forth in Section 204 to be placed on all
Global Notes issued under this Indenture.

          “Initial
Subsidiary Guarantors” means each of American Medical Laboratories
Incorporated, AmeriPath Consolidated Labs, Inc., AmeriPath Florida, LLC,
AmeriPath Hospital Services Florida, LLC, AmeriPath Indiana, LLC, AmeriPath
Kentucky, Inc., AmeriPath Marketing USA, Inc., AmeriPath Michigan, Inc.,
AmeriPath Mississippi, Inc., AmeriPath New York, LLC, AmeriPath North Carolina,
Inc., AmeriPath Ohio, Inc., AmeriPath Pennsylvania, LLC, AmeriPath
Philadelphia, Inc., AmeriPath SC, Inc., AmeriPath Texas, LP, AmeriPath
Wisconsin, LLC, AmeriPath Youngstown Labs, Inc., AmeriPath, Inc., AmeriPath,
LLC, AML Inc., Anatomic Pathology Services, Inc., API No. 2, LLC, APL
Properties Limited Liability Company, Arizona Pathology Group, Inc., Central
Plains Holdings, Inc., Central Plains Laboratories, LLC, Dermatopathology
Services, Inc., Diagnostic Pathology Management Services, LLC, Diagnostic
Reference Services Inc., DPD Holdings, Inc., Enterix Inc., ExamOne World Wide
of NJ, Inc., ExamOne World Wide, Inc., FNA Clinics of America, Inc. (f/k/a
Unilab Acquisition Corporation), Focus Diagnostics, Inc., Focus Technologies
Holding Company, HemoCue, Inc., Kailash B. Sharma, M.D., Inc., LabOne of Ohio,
Inc., LabOne, Inc., MetWest Inc., Nichols Institute Diagnostics, Ocmulgee
Medical Pathology Association, Inc., O’Quinn Medical Pathology Association,
LLC, Osborn Group Inc., Pathology Building Partnership, PCA of Denver, Inc.,
PCA of Nashville, Inc., Peter G. Klacsmann, M.D., Inc., Quest Diagnostics
Clinical Laboratories, Inc., Quest Diagnostics Finance Incorporated, Quest
Diagnostics Holdings Incorporated, Quest Diagnostics Incorporated (MD), Quest
Diagnostics Incorporated (MI), Quest Diagnostics Incorporated (NV), Quest
Diagnostics Investments Incorporated, Quest Diagnostics LLC (CT), Quest
Diagnostics LLC (IL), Quest Diagnostics LLC (MA), Quest Diagnostics Nichols
Institute (f/k/a Quest Diagnostics Incorporated (CA)), Quest Diagnostics
Nichols Institute, Inc., Quest Diagnostics of Pennsylvania Inc., Regional
Pathology Consultants, LLC, Rocky Mountain Pathology, LLC, Sharon G. Daspit,
M.D., Inc., Shoals Pathology Associates, Inc., Specialty Laboratories, Inc.,
Strigen, Inc., Systematic Business Services, Inc., TID Acquisition Corp.,
Unilab Corporation.

          “Investment Grade Rating” means a
rating equal to or higher than Baa3 (or the equivalent) by Moody’s and BBB- (or
the equivalent) by S&P, and the equivalent investment grade credit rating
from any additional rating agency or Rating Agencies selected by the Company. 

          “Moody’s” means Moody’s Investors
Service, Inc. 

3

          “Rating Agencies” means (1) each
of Moody’s and S&P and Fitch, to the extent Fitch makes a rating of the
Notes publicly available; and (2) if any of Moody’s and S&P or Fitch,
to the extent Fitch makes a rating of the Notes publicly available, ceases to
rate the Notes or fails to make a rating of the Notes publicly available for
reasons outside of the control of the Company, a “nationally recognized
statistical rating organization” within the meaning of
Rule 15c3-1(c)(2)(vi)(F) under the Exchange Act selected by the Company
(as certified by a resolution of the Board of Directors of the Company) as a
replacement agency for Moody’s or S&P or Fitch (if applicable) or all of
them, as the case may be. 

          “Rating Event” means the rating on the
Notes is lowered by each of the Rating Agencies and the Notes are rated below
an Investment Grade Rating by each of the Rating Agencies on any day within the
60-day period (which 60-day period shall be extended so long as the rating of
the Notes is under publicly announced consideration for possible downgrade by
any of the Rating Agencies) after the earlier of (1) the occurrence of a Change
of Control and (2) public notice of the occurrence of a Change of Control or
the intention of the Company to effect a Change of Control; provided, however,
that a Rating Event otherwise arising by virtue of a particular reduction in
rating will not be deemed to have occurred in respect of a particular Change of
Control (and thus will not be deemed a Rating Event for purposes of the
definition of Change of Control Triggering Event) if the Rating Agencies making
the reduction in rating to which this definition would otherwise apply do not
announce or publicly confirm or inform the trustee in writing at its request or
the request of the Company that the reduction was the result, in whole or in
part, of any event or circumstance comprised of or arising as a result of, or
in respect of, the applicable Change of Control (whether or not the applicable
Change of Control has occurred at the time of the Rating Event.).

          “S&P” means Standard &
Poor’s Ratings Services, a division of The McGraw-Hill Companies, Inc. 

          “Specified
Subsidiaries” means AmeriPath Group Holdings, Inc., AmeriPath Holdings, Inc.,
AmeriPath Intermediate Holdings, Inc., and MedPlus, Inc.

          “Voting
Stock” means, with respect to any specified “person” (as that term is used in
Section 13(d)(3) of the Exchange Act) as of any date, the capital stock of
such person that is at the time entitled to vote generally in the election of
the board of directors of such person.

ARTICLE II.

FORM AND TERMS OF THE NOTES

                    SECTION
2.1. Form and Dating.

                    The
Notes due 2017, the applicable Subsidiary Guarantees and the Trustee’s
certificate of authentication shall be substantially in the form of Exhibit
A attached hereto. The Notes due 2037, the applicable Subsidiary Guarantees
and the Trustee’s certificate of authentication shall be substantially in the
form of Exhibit B attached hereto. The Notes shall be executed on behalf
of the Company by its Chief Executive
Officer, the Chief Financial Officer, the Controller or the Treasurer, and the
Secretary, under its corporate seal reproduced thereon. The Notes may
have notations, legends or endorsements required by law, stock exchange rules
or usage. Each Note shall be dated the date of its authentication. The Notes
and any beneficial interest in the Notes shall be in minimum denominations of
$2,000 and integral multiples of $1,000 in excess thereof. 

4

                    The
terms and notations contained in the Notes shall constitute, and are hereby
expressly made, a part of this Indenture and the Company, the Subsidiary
Guarantors and the Trustee, by their execution and delivery of this Indenture,
expressly agree to such terms and provisions and to be bound thereby.

	
 

	
 

	
 

	
          (a)
  Global Notes. The Global Notes of
  each series designated herein shall be issued initially in the form of one or
  more fully registered global notes, which shall be deposited on behalf of the
  purchasers of the Notes represented thereby with the Depository Trust
  Company, New York, New York (the “Depository”) and registered in the name of
  Cede & Co., the Depository’s nominee, duly executed by the Company,
  authenticated by the Trustee and with guarantees endorsed thereon as
  hereinafter provided. The aggregate principal amount of outstanding Notes may
  from time to time be increased or decreased by adjustments made on the
  records of the Trustee and the Depository or its nominee as hereinafter
  provided.

	
 

	
 

	
 

	
          The
  Global Notes may not be transferred except by the Depository, in whole and
  not in part, to another nominee of the Depository or to a successor of the
  Depository or its nominee. If at any time the Depository for the Notes
  notifies the Company that the Depository is unwilling or unable to continue
  as Depository for the Global Notes and a successor Depository for the Global
  Notes is not appointed by the Company within 90 days after delivery of such
  notice, then the Company shall execute, and the Trustee shall, upon receipt
  of a Company Order, for authentication, authenticate and deliver, Definitive
  Notes in an aggregate principal amount equal to the principal amount of the
  Global Notes in exchange for such Global Note. 

	
 

	
 

	
 

	
          (b)
  Book-Entry Provisions. This Section 2.1(b) shall apply only to the Global
  Notes deposited with or on behalf of the Depository. 

	
 

	
 

	
 

	
          The
  Company shall execute and the Trustee shall, in accordance with this Section
  2.1(b), authenticate and deliver the Global Notes that shall be registered in
  the name of the Depository or the nominee of the Depository and shall be
  delivered by the Trustee to the Depository or pursuant to the Depository’s
  instructions.

	
 

	
 

	
 

	
          Depository
  Participants shall have no rights either under this Indenture or with respect
  to any Global Notes held on their behalf by the Depository or under such
  Global Notes. The Depository shall be treated by the Company, the Subsidiary
  Guarantors, the Trustee and any agent of the Company, the Subsidiary
  Guarantors or the Trustee as the absolute owner of such Global Note for all
  purposes under this Indenture. Notwithstanding the foregoing, nothing herein
  shall prevent the Company or the Trustee from giving effect to any written
  certification, proxy or other authorization furnished by the Depository or
  impair, as between the Depository and the Depository Participants, the
  operation of customary practices of such Depository governing the exercise of
  the rights of an owner of a beneficial interest in the Global Notes.

	
 

	
 

	
 

	
          (c)
  Definitive Notes. Notes issued in certificated form shall be substantially in
  the form of Exhibit A or Exhibit B, as applicable, attached hereto, but
  without including the text referred to therein as applying only to Global
  Notes. Except as provided above in subsection (a), owners of beneficial
  interests in the Global Notes will not be entitled to receive physical
  delivery of certificated Notes.

	
 

	
 

	
 

	
          (d)
  Transfer and Exchange of the Notes. The transfer and exchange of beneficial
  interests in the Global Notes shall be effected through the Depository, in
  accordance with this Indenture and the procedures of the Depository therefor.
  Beneficial interests in the Global Notes 

5

	
 

	
 

	
 

	
may be transferred to Persons who take delivery thereof in the form
  of a beneficial interest in the Global Notes.

	
 

	
 

	
 

	
          (e) Paying Agent. The Company appoints The Bank of New York as agent
  of the Company for the payment of the principal of (and premium, if any) and
  interest on the Notes; and that the Corporate Trust Office of The Bank of New
  York in the Borough of Manhattan, the City of New York, be and hereby is,
  designated as the office or agency in the Borough of Manhattan where the
  Notes may be presented for payment and where notices to or demands upon the
  Corporation in respect of the Notes and the Indenture pursuant to which the
  Notes are to be issued may be served. 

	
 

	
 

	
 

	
          SECTION
  2.2. Terms of the Notes. 

	
 

	
 

	
 

	
          The
  following terms relating to the Notes are hereby established: 

	
 

	
 

	
 

	
                    (a)
  The Notes due 2017 shall constitute a series of Securities having the title
  “Senior Notes due 2017”
  and the Notes due 2037 shall
  constitute a separate series of Securities having the title “Senior Notes due
  2037.”

	
 

	
 

	
 

	
                    (b)
  The aggregate principal amount of the Notes due 2017 that may be initially authenticated and
  delivered under the Indenture (except for Notes due 2017 authenticated and delivered upon
  registration of, transfer of, or in exchange for, or in lieu of, other Notes
  due 2017 pursuant to Sections
  304, 305, 306, 906 or 1107 of the Indenture) shall be $375,000,000. The aggregate principal amount of the
  Notes due 2037 that may be
  initially authenticated and delivered under the Indenture (except for Notes
  due 2037 authenticated and
  delivered upon registration of, transfer of, or in exchange for, or in lieu
  of, other Notes due 2037
  pursuant to Sections 304, 305, 306, 906 or 1107 of the Indenture) shall be $425,000,000. The Company may from time to time,
  without the consent of the Holders of Notes of either series, issue
  additional Notes (in any such case “Additional Notes”) of either series
  having the same ranking and the same interest rate, maturity and other terms
  as the Notes of that series. Any additional Notes of a series and the
  existing Notes of that series will constitute a single series under the
  Indenture and all references to the relevant Notes shall include the
  Additional Notes unless the context otherwise requires. 

	
 

	
 

	
 

	
                    (c)
  The entire outstanding principal of the Notes due 2017 shall be payable on July 1, 2017,and the entire outstanding principal of
  the Notes due 2037 shall be
  payable on July 1, 2037.

	
 

	
 

	
 

	
                    (d)
  The rate at which the Notes due 2017 shall bear interest shall be 6.40% per annum and the rate at which the Notes due 2037 shall
bear interest shall be 6.95% per annum; the date from which interest
  shall accrue on the Notes shall be June 22, 2007, or the most recent Interest Payment Date to which interest
  has been paid or provided for; the Interest Payment Dates for the Notes shall
  be July 1 and January 1 of each year, beginning January 1, 2008; the interest
  so payable, and punctually paid or duly provided for, on any Interest Payment
  Date, will be paid, in immediately available funds, to the Persons in whose
  names the Notes (or one or more Predecessor Securities) is registered at the
  close of business on the Regular Record Date for such interest, which shall
  be June 15 or December 15, as the case may be, next preceding such Interest
  Payment Date. Any such interest not punctually paid or duly provided for shall forthwith cease to be payable to
  the respective Holders on such Regular Record Date, and such Defaulted Interest, may be paid to the Persons in whose names the Notes (or one
  or more Predecessor Securities) is registered at the close of business on a
  Special Record Date for the payment of such Defaulted 

6

	
 

	
 

	
 

	
Interest to be fixed by
  the Trustee, notice whereof shall be given to Holders of Notes not less than
  10 days prior to such Special Record Date, or may be paid at any time in any
  other lawful manner not inconsistent with requirements of any securities
  exchange on which the Notes may be listed, and upon such notice as may be
  required by such exchange, all as more fully provided in said Indenture.
  Payment of principal and interest on this Note will be made at the Corporate
  Trust Office of the Trustee or such other office or agency of the Company as
  may be designated for such purpose, in such coin or currency of the United
  States of America as at the time of payment is legal tender for payment of
  public and private debts; provided, however, that each installment of
  interest and principal on this Notes may at the Company’s option be paid in
  immediately available funds by transfer to an account maintained by the payee
  located in the United States.

	
 

	
 

	
 

	
                    (e)
  Each of the Notes due 2017 and the Notes due 2037 shall be issuable in whole
  in the registered form of one or more Global Notes (without coupons), and the
  Depository for such Global Notes shall be the Depository Trust Company, New
  York, New York.

	
 

	
 

	
 

	
                    (f)
  The Redemption Amount of Basis Points applicable to the Notes used to
  calculate the Redemption Price pursuant to Section 1108 of the Indenture shall be 25 basis points for the Senior Notes due 2017,
and 30 basis points for the Senior Notes due 2037. 

	
 

	
 

	
 

	
                    (g)
  Each of the Notes due 2017 and the Notes
  due 2037 shall be
  guaranteed by the Initial Subsidiary Guarantors in accordance with Article
  Sixteen of the Indenture.

                    SECTION
2.3 Application of the Terms of the Second Supplemental Indenture. 

                    All
provisions of the Second Supplemental Indenture, unless otherwise expressly
referred to herein, shall not apply to the Notes and shall not form a part of
this Indenture.

                    SECTION
2.4. Application of the Article of the Indenture Regarding Guarantees. 

                    Except
as may be provided in a Future Supplemental Indenture, the provisions of
Article Sixteen of the Indenture, as amended, shall apply to the Notes;
provided, however, for the avoidance of doubt, that the Specified Subsidiaries
shall not be subject to the provisions of Article Sixteen of the Indenture
until such time, if any, that the Specified Subsidiaries become Subsidiary
Guarantors.

                    SECTION
2.5. Application of the Article of the Indenture Regarding Redemption of
Securities.

                    Except as may be provided in
a Future Supplemental Indenture, the provisions of Article Eleven of the
Indenture, as amended, shall apply to the Notes.

                    SECTION
2.6. Application of the Article of the Indenture Relating to a Sinking Fund.

                    Except
as may be provided in a Future Supplemental Indenture, none of the Notes shall
be entitled to the benefit of any sinking fund, and the provisions of the
Indenture relating to a sinking fund, including Article Twelve and Subsection
(3) of Section 501 of the Indenture, shall not apply to any of the Notes.

7

                    SECTION
2.7. Additional Events of Default.

                    Except
as may be provided by a Future Supplemental Indenture, for the benefit of the
holders of the Notes, Section 501(7)(A) of the Indenture shall be amended by
deleting the words “$100 million” in the second line thereof and, in their
place, adding the words “$200 million;” and Section 501(7)(B) of the Indenture
shall be amended by deleting the words “$100 million” in the sixth line thereof
and, in their place, adding the words “$200 million”.

                    SECTION
2.8. Application of the Article of the Indenture Regarding Defeasance and
Covenant Defeasance.

                    Except
as may be provided by a Future Supplemental Indenture, the provisions of
Article Fourteen of the Indenture, including the provisions relating to
defeasance and covenant defeasance of the Securities under Sections 1402 and
1403, respectively, of the Indenture shall apply to the Notes.

                    SECTION
2.9. Application of the Article of the Indenture Regarding Repayment at the
Option of Holders.

                    Except
as may be provided by a Future Supplemental Indenture, the provisions of
Article Thirteen of the Indenture shall not apply to the Notes.

                    SECTION
2.10. Limitation on Restricted Payments to Certain Non-Guarantor
Subsidiaries.

                    Except
as may be provided by a Future Supplemental Indenture, for the benefit of
holders of the Notes, a new Section 1012 shall be added to the Indenture as
follows:

                    Section
1012 Limitation on Restricted Payments to Certain Non-Guarantor Subsidiaries.

                    The
Company shall not, and shall not permit any Subsidiary to:

	
 

	
 

	
 

	
          (1) declare
  or pay any dividend or make any distribution to the Specified Subsidiaries on
  or in respect of its Capital Stock,

	
 

	
 

	
 

	
          
  (2) purchase, redeem, retire or otherwise acquire for value from the Specified
  Subsidiaries any of its Capital Stock, or

	
 

	
 

	
 

	
          (3) purchase
  or otherwise acquire any assets, or purchase or otherwise acquire, redeem,
  retire or repay any Indebtedness of the Specified Subsidiaries, or 

	
 

	
 

	
 

	
          (4) make
  any investment in or make any loan to or transfer any assets to any of the
  Specified Subsidiaries.

	
 

	
 

	
 

	
          This
  Section 1012 shall permanently cease to be in effect when each of the
  Specified Subsidiaries becomes a Subsidiary Guarantor.

8

                    SECTION
2.11. Limitations on Subsidiary Indebtedness and Preferred Stock.

                    Except
as may be provided by a Future Supplemental Indenture, for the benefit of the
holders of the Notes, Section 1011 of the Indenture shall be amended by adding
a new subsection 1011(k) as follows:

	
 

	
 

	
 

	
          (k)
  any guarantee of Indebtedness of the Company by the Specified Subsidiaries or
  any other Subsidiary of the Company in anticipation of such Subsidiary
  becoming a Subsidiary Guarantor pursuant to Article Sixteen of the Indenture.

                    SECTION
2.12. Repurchase of Notes Upon a Change of Control. 

                    Except
as may be provided by a Future Supplemental Indenture, for the benefit of the
holders of the Notes, a new Section 315 shall be added to the Indenture as
follows:

                    Section
315 Repurchase of Notes Upon a Change of Control.

	
 

	
 

	
 

	
          (a)
  If a Change of Control Triggering Event occurs, unless the Company has
  exercised its option to redeem the Notes as described in Section 1108, the
  Company shall make an offer to repurchase all or any part (equal to $2,000 or
  an integral multiple of $1,000 in excess thereof) of the Notes pursuant to
  the offer described below (the “Change of Control Offer”) on the terms set
  forth in the Notes. In the Change of Control Offer, the Company shall offer
  payment in cash equal to 101% of the aggregate principal amount of Notes
  repurchased, plus accrued and unpaid interest, if any, on the Notes
  repurchased to the date of repurchase (the “Change of Control Payment”).
  Within 30 days following any Change of Control Triggering Event or, at
  the option of the Company, prior to any Change of Control, but after the
  public announcement of the transaction that constitutes or may constitute the
  Change of Control, the Company shall mail a notice to holders of Notes
  describing the transaction that constitutes or may constitute the Change of
  Control Triggering Event and offering to repurchase the Notes on the date
  specified in the notice, which date will be no earlier than 30 days and
  no later than 60 days from the date such notice is mailed (the “Change
  of Control Payment Date”). The notice shall, if mailed prior to the date of
  consummation of the Change of Control, state that the offer to purchase is
  conditioned on the Change of Control Triggering Event occurring on or prior
  to the Change of Control Payment Date. 

	
 

	
 

	
 

	
          (b)
  The Company shall comply with the requirements of Rule 14e-1 under the
  Securities Exchange Act of 1934, as amended, and any other securities laws
  and regulations thereunder to the extent those laws and regulations are
  applicable in connection with the repurchase of the Notes as a result of a
  Change of Control Triggering Event. To the extent that the provisions of any
  such securities laws or regulations conflict with the Change of Control
  provisions of the Notes, The Company will comply with the applicable
  securities laws and regulations and will not be deemed to have breached its
  obligations under the Change of Control provisions of the Notes by virtue of
  any such conflict. 

	
 

	
 

	
 

	
          (c)
  On the Change of Control Payment Date, the Company shall, to the extent
  lawful: 

9

	
 

	
 

	
 

	
 

	
 

	
          (1)
  accept for payment all Notes or portions of Notes properly tendered pursuant
  to the Change of Control Offer; 

	
 

	
 

	
 

	
 

	
 

	
          (2)
  deposit with the Paying Agent an amount equal to the Change of Control
  Payment in respect of all Notes or portions of Notes properly tendered; and 

	
 

	
 

	
 

	
 

	
 

	
          (3)
  deliver or cause to be delivered to the Trustee the Notes properly accepted
  together with an Officers’ Certificate stating the aggregate principal amount
  of Notes or portions of Notes being purchased. 

	
 

	
 

	
 

	
 

	
          (d)
  The Company shall not be required to make a Change of Control Offer upon the
  occurrence of a Change of Control Triggering Event if a third party makes such
  an offer in the manner, at the times and otherwise in compliance with the
  requirements for an offer made by the Company and the third party repurchases
  all Notes properly tendered and not withdrawn under its offer. In addition,
  the Company shall not repurchase any Notes if there has occurred and is
  continuing on the Change of Control Payment Date an event of default under
  this Indenture, other than a default in the payment of the Change of Control
  Payment upon a Change of Control Triggering Event.

ARTICLE III.

MISCELLANEOUS

                    SECTION
3.1. Governing Law.

                    This
Tenth Supplemental Indenture and the Notes shall be governed by and construed
in accordance with the laws of the State of New York, without regard to
principles of conflicts of laws. This Tenth Supplemental Indenture is subject
to the provisions of the Trust Indenture Act that are required to be part of
this Indenture and shall, to the extent applicable, be governed by such
provisions.

                    SECTION
3.2. Separability.

                    In
case any provision in this Tenth Supplemental Indenture or in any Securities,
including the Notes, shall be invalid, illegal or unenforceable, the validity,
legality and enforceability of the remaining provisions shall not in any way be
affected or impaired thereby. 

                    SECTION
3.3. Counterparts.

                    This
Tenth Supplemental Indenture may be executed in any number of counterparts,
each of which so executed shall be deemed to be an original, but all such
counterparts shall together constitute but one and the same Supplemental
Indenture.

                    SECTION
3.4. Ratification.

                    The
Base Indenture, as supplemented and amended by the First Supplemental
Indenture, the Second Supplemental Indenture, the Third Supplemental Indenture,
the Fourth Supplemental Indenture, the Fifth Supplemental Indenture, the Sixth
Supplemental Indenture, the Seventh Supplemental 

10

Indenture, the
Eighth Supplemental Indenture, the Ninth Supplemental Indenture and this Tenth
Supplemental Indenture is in all respects ratified and confirmed. The Base
Indenture, the First Supplemental Indenture, the Third Supplemental Indenture,
the Fourth Supplemental Indenture, the Fifth Supplemental Indenture, Sixth
Supplemental Indenture, the Seventh Supplemental Indenture, the Eighth
Supplemental Indenture, the Ninth Supplemental Indenture and this Tenth
Supplemental Indenture shall be read, taken and construed as one and the same
instrument. All provisions included in this Tenth Supplemental Indenture
supersede any conflicting provisions included in the Base Indenture unless not
permitted by law. The Trustee accepts the trusts created by the Indenture, as
supplemented by this Tenth Supplemental Indenture, and agrees to perform the
same upon the terms and conditions of the Indenture, as supplemented by this
Tenth Supplemental Indenture. 

                    SECTION
3.5. Effectiveness. 

                    The
provisions of this Tenth Supplemental Indenture shall become effective as of
the date hereof.

[Remainder of page intentionally left blank.]

11

                    IN
WITNESS WHEREOF, the parties hereto have caused this Tenth Supplemental
Indenture to be duly executed, and their respective corporate seals to be
hereunto affixed and attested, all as of the date first above written.

	
 

	
 

	
 

	
 

	
 

	
QUEST
  DIAGNOSTICS INCORPORATED

	
 

	
 

	
 

	
By: 

	
/s/ 

	
  Robert A.
  Hagemann

	
 

	
 

	

	
 

	
 

	
     Name:
  

	
  Robert A.
  Hagemann

	
 

	
 

	
     Title:
  

	
  Senior Vice
  President and

	
 

	
 

	
 

	
  Chief
  Financial Officer

12

	
 

	
 

	
 

	
QUEST
  DIAGNOSTICS HOLDINGS INCORPORATED

	
 

	
QUEST
  DIAGNOSTICS CLINICAL LABORATORIES, INC.

	
 

	
QUEST
  DIAGNOSTICS NICHOLS INSTITUTE

	
 

	
QUEST
  DIAGNOSTICS INCORPORATED (NV)

	
 

	
QUEST
  DIAGNOSTICS INCORPORATED (MD)

	
 

	
QUEST
  DIAGNOSTICS LLC (IL)

	
 

	
QUEST
  DIAGNOSTICS LLC (CT)

	
 

	
QUEST DIAGNOSTICS LLC (MA)

	
 

	
QUEST
  DIAGNOSTICS INCORPORATED (MI)

	
 

	
QUEST
  DIAGNOSTICS OF PENNSYLVANIA INC.

	
 

	
AML INC.

	
 

	
AMERICAN
  MEDICAL LABORATORIES INCORPORATED

	
 

	
APL
  PROPERTIES LIMITED LIABILITY COMPANY

	
 

	
METWEST INC.

	
 

	
QUEST DIAGNOSTICS
  NICHOLS INSTITUTE, INC.

	
 

	
DPD
  HOLDINGS, INC.

	
 

	
DIAGNOSTIC
  REFERENCE SERVICES INC.

	
 

	
PATHOLOGY
  BUILDING PARTNERSHIP

	
 

	
UNILAB
  CORPORATION

	
 

	
FNA CLINICS
  OF AMERICA, INC. 

	
 

	
LABONE, INC

	
 

	
EXAMONE
  WORLD WIDE, INC.

	
 

	
EXAMONE
  WORLD WIDE OF NJ, INC.

	
 

	
CENTRAL
  PLAINS HOLDINGS, INC.

	
 

	
CENTRAL PLAINS LABORATORIES, LLC

	
 

	
LABONE OF
  OHIO, INC.

	
 

	
OSBORN GROUP
  INC.

	
 

	
SYSTEMATIC
  BUSINESS SERVICES, INC.

	
 

	
 

	
 

	
 

	
 

	
By:

	
/s/

	
  Robert A.
  Hagemann

	
 

	
 

	

	
 

	
 

	
         Name:

	
  Robert A.
  Hagemann

	
 

	
 

	
         Title:

	
  Vice
  President

13

	
 

	
 

	
 

	
 

	
 

	
NICHOLS
  INSTITUTE DIAGNOSTICS

	
 

	
 

	
 

	
 

	
By: 

	
/s/

	
  Robert A.
  Hagemann

	
 

	
 

	

	
 

	
 

	
         Name:
  

	
  Robert A.
  Hagemann

	
 

	
 

	
         Title:
  

	
  Vice
  President

14

	
 

	
 

	
 

	
 

	
 

	
FOCUS
  TECHNOLOGIES HOLDING COMPANY 

	
 

	
FOCUS
  DIAGNOSTICS, INC.

	
 

	
 

	
 

	
By:

	
/s/

	
  Robert A.
  Hagemann

	
 

	
 

	

	
 

	
 

	
          Name:

	
  Robert A.
  Hagemann

	
 

	
 

	
          Title:

	
  Vice
  President

15

	
 

	
 

	
 

	
AMERIPATH,
  INC. 

	
 

	
AMERIPATH
  CONSOLIDATED LABS, INC. 

	
 

	
AMERIPATH
  FLORIDA, LLC 

	
 

	
AMERIPATH
  HOSPITAL SERVICES FLORIDA, LLC 

	
 

	
AMERIPATH
  INDIANA, LLC 

	
 

	
AMERIPATH
  KENTUCKY, INC. 

	
 

	
AMERIPATH
  MARKETING USA, INC. 

	
 

	
AMERIPATH
  MICHIGAN, INC. 

	
 

	
AMERIPATH
  MISSISSIPPI. INC. 

	
 

	
AMERIPATH
  NEW YORK, LLC 

	
 

	
AMERIPATH
  NORTH CAROLINA, INC. 

	
 

	
AMERIPATH
  OHIO, INC. 

	
 

	
AMERIPATH
  PENNSYLVANIA, LLC 

	
 

	
AMERIPATH
  PHILADELPHIA, INC. 

	
 

	
AMERIPATH
  SC, INC. 

	
 

	
AMERIPATH
  TEXAS, LP. 

	
 

	
AMERIPATH
  YOUNGSTOWN LABS, INC. 

	
 

	
AMERIPATH
  WISCONSIN, LLC 

	
 

	
AMERIPATH,
  LLC 

	
 

	
API NO. 2, LLC

	
 

	
ANATOMIC
  PATHOLOGY SERVICES, INC. 

	
 

	
ARIZONA
  PATHOLOGY GROUP, INC. 

	
 

	
DERMATOPATHOLOGY
  SERVICES, INC. 

	
 

	
DIAGNOSTIC
  PATHOLOGY MANAGEMENT SERVICES, LLC 

	
 

	
KAILASH B.
  SHARMA, M.D., INC.

	
 

	
OCMULGEE
  MEDICAL PATHOLOGY ASSOCIATION INC.

	
 

	
O’QUINN
  MEDICAL PATHOLOGY ASSOCIATION, LLC

	
 

	
PCA OF
  DENVER, INC. 

	
 

	
PCA OF
  NASHVILLE, INC. 

	
 

	
PETER G.
  KLACSMANN M.D., INC. 

	
 

	
REGIONAL PATHOLOGY
  CONSULTANTS, LLC 

	
 

	
ROCKY
  MOUNTAIN PATHOLOGY, LLC

	
 

	
SHARON G.
  DASPIT, M.D., INC. 

	
 

	
SHOALS
  PATHOLOGY ASSOCIATES, INC.

	
 

	
SPECIALTY
  LABORATORIES, INC.

	
 

	
STRIGEN,
  INC. 

	
 

	
TID ACQUISITION CORP. 

	
 

	
 

	
 

	
 

	
 

	
By:

	
/s/

	
  Robert A.
  Hagemann

	
 

	
 

	

	
 

	
 

	
          Name:

	
  Robert A.
  Hagemann

	
 

	
 

	
          Title:

	
  Vice
  President 

16

	
 

	
 

	
 

	
 

	
 

	
ENTERIX INC.
  

	
 

	
HEMOCUE,
  INC.

	
 

	
 

	
 

	
By: 

	
/s/

	
  Robert A.
  Hagemann

	
 

	
 

	

	
 

	
 

	
          Name:

	
  Robert A.
  Hagemann

	
 

	
 

	
          Title:

	
  Vice
  President

17

	
 

	
 

	
 

	
 

	
 

	
QUEST
  DIAGNOSTICS INVESTMENTS INCORPORATED 

	
 

	
QUEST
  DIAGNOSTICS FINANCE INCORPORATED

	
 

	
 

	
 

	
By: 

	
/s/ 

	
  Stephen A.
  Calamari

	
 

	
 

	

	
 

	
 

	
          Name:
  

	
  Stephen A.
  Calamari

	
 

	
 

	
          Title:
  

	
  Treasurer

18

	
 

	
 

	
 

	
 

	
 

	
THE BANK OF
  NEW YORK,

	
 

	
 

	
         as
  Trustee

	
 

	
 

	
 

	
 

	
By: 

	
   /s/ Robert A. Massimillo

	
 

	
 

	

	
 

	
 

	
         Name:

	
  Robert A.
  Massimillo

	
 

	
 

	
         Title:

	
  Vice
  President

19

EXHIBIT A

Form of 6.40%
Senior Note due 2017

                    [The following legends apply only if the Note is a
Global Note:

                    THIS
NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED
TO AND IS REGISTERED IN THE NAME OF A DEPOSITORY OR A NOMINEE THEREOF. THIS
NOTE MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A NOTE REGISTERED, AND NO
TRANSFER OF THIS NOTE IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY
PERSON OTHER THAN SUCH DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED
CIRCUMSTANCES DESCRIBED IN THE INDENTURE.

                    UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED
REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY TO THE ISSUER OR ITS AGENT FOR
REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT AND SUCH CERTIFICATE ISSUED IN
EXCHANGE FOR THIS CERTIFICATE IS REGISTERED IN THE NAME OF CEDE & CO., OR
SUCH OTHER NAME AS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY,
ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON
IS WRONGFUL, SINCE THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST
HEREIN.]

A-1

QUEST
DIAGNOSTICS INCORPORATED

6.40%
Senior Note due 2017

Unconditionally
guaranteed as to payment of

principal of and interest by

the Subsidiary Guarantors

	
   

  	
   

  
	
  No. 0 (Specimen)

  	
  $375,000,000

  

CUSIP:
74834L AM2

                    Quest
Diagnostics Incorporated, a Delaware corporation (herein called the “Company,”
which term includes any successor Person under the Indenture hereinafter
referred to), for value received, hereby promises to pay to Cede & Co., or
registered assigns, the principal sum of $375,000,000 on July 1, 2017 (the
“Stated Maturity”) (except to the extent redeemed or repaid prior to the Stated
Maturity) and to pay interest thereon from June 22, 2007 or from the most
recent Interest Payment Date to which interest has been paid or duly provided
for semi-annually at the rate of 6.40% per annum, on July 1 and January 1,
commencing with January 1, 2008, on the Stated Maturity and on any Redemption
Date (each such date, an “Interest Payment Date”) until the principal hereof is
paid or made available for payment. 

                    Payment
of Interest. The interest so payable, and punctually paid or made available
for payment, on any Interest Payment Date, will, as provided in the Indenture,
be paid, in immediately available funds, to the Person in whose name this Note
(or one or more Predecessor Securities) is registered at the close of business
on June 15 or December 15 (whether or not a Business Day, as defined in the
Indenture), as the case may be, next preceding such Interest Payment Date (the
“Regular Record Date”). Any such interest not punctually paid or duly provided
for (“Defaulted Interest”) will forthwith cease to be payable to the Holder on
such Regular Record Date, and such Defaulted Interest, may be paid to the
Person in whose name this Note (or one or more Predecessor Securities) is
registered at the close of business on a special record date (the “Special
Record Date”) for the payment of such Defaulted Interest to be fixed by the
Trustee, notice whereof shall be given to Holders of Notes not less than ten
days prior to such Special Record Date, or may be paid at any time in any other
lawful manner not inconsistent with requirements of any securities exchange on
which the Notes may be listed, and upon such notice as may be required by such
exchange, all as more fully provided in said Indenture. 

                    Place
of Payment. Payment of interest on this Note will be made at the Corporate
Trust Office of the Trustee or such other office or agency of the Company as
may be designated for such purpose, in such coin or currency of the United
States of America as at the time of payment is legal tender for payment of
public and private debts; provided, however,
that each installment of interest and payment of principal on this Notes may at
the Company’s option be paid in immediately available funds by transfer to an
account maintained by the payee located in the United States. Payment of the
principal of this Note on the Stated Maturity will be made against presentation
of this Note at the office or agency of the Company maintained for that purpose
in the Borough of Manhattan, The City of New York, in such coin or currency of
the United States of America as at the time of payment is legal tender for the
payment of public and private debts. 

                    Time
of Payment. In any case where any Interest Payment Date, Redemption Date,
Stated Maturity shall not be a Business Day at any Place of Payment, then
(notwithstanding any other provision of the Indenture or this Note), payment of
principal or interest, if any, need not be made at such Place of Payment on
such date, but may be made on the next succeeding Business Day at such Place of
Payment with the same force and effect as if made on the Interest Payment Date,
Redemption Date, or at

A-2

Stated Maturity; provided that no interest
shall accrue on the amount so payable for the period from and after such
Interest Payment Date, Redemption Date, Repayment Date, or Stated Maturity, as
the case may be.

                    Legends.
The statements set forth in the restrictive legends above are an integral part
of the terms of this Note and by acceptance hereof each Holder of this Note
agrees to be subject to and bound by the terms and provisions set forth in such
legend. 

                    General.
This Note is one of a duly authorized issue of securities (herein called the
“Securities”) of the Company, issued and to be issued in one or more series under
an indenture, dated as of June 27, 2001 (the “Base Indenture”), between the
Company and The Bank of New York, Trustee (herein called the “Trustee”, which
term includes any successor trustee under the Indenture with respect to a
series of which this Note is a part), to which Base Indenture and all
indentures supplemental thereto, including the supplemental indenture dated
June 22, 2007 (the “Supplemental Indenture”), reference is hereby made for a
statement of the respective rights, limitations of rights, duties and
immunities thereunder of the Company, the Trustee and the Holders of the
Securities, and of the terms upon which the Securities are, and are to be,
authenticated and delivered. This Note is one of a duly authorized series of
Securities designated as “6.40% Senior Notes due 2017” (collectively, the
“Notes”), initially limited in aggregate principal amount to $375,000,000.

                    Further
Issuance. The Company may from time to time, without the consent of the
Holders of Notes of this series, issue additional Notes (the “Additional
Notes”) of this series having the same ranking and the same interest rate,
maturity and other terms as the Notes of this series. Any Additional Notes of
this series and the Notes of this series will constitute a single series under
the Indenture and all references to the Notes of this series shall include the
Additional Notes unless the context otherwise requires. 

                    [The
following paragraph applies only if the Note is a Global Note:

                    Book-Entry.
This Note is a Global Note representing $375,000,000 of the Notes. This Note is
a “book entry” Note and is being registered in the name of Cede & Co. as
nominee of The Depository Trust Company (the “Depository “), a clearing agency.
Subject to the terms of the Indenture, this Note will be held by a clearing
agency or its nominee, and beneficial interest will be held by beneficial
owners through the book-entry facilities of such clearing agency or its nominee
in minimum denominations of $2,000 and integral multiples of $1,000 in excess
thereof. As long as this Note is registered in the name of the Depository or
its nominee, the Trustee will make payments of principal and interest on this
Note by wire transfer of immediately available funds to the Depository or its
nominee. Notwithstanding the above, the final payment on this Note will be made
after due notice by the Trustee of the pendency of such payment and only upon
presentation and surrender of this Note at its Corporate Trust Office or such
other offices or agencies appointed by the Trustee for that purpose and such
other locations provided in the Indenture.]

                    Guarantees.
This Note is entitled to the benefits of the Subsidiary Guarantees by each of
the Subsidiary Guarantors of the due and punctual payment and performance of
the Guarantor Obligations made in favor of the Trustee for the benefit of the
Holder of this Note. Reference is hereby made to Article Sixteen of the
Indenture for a statement of the respective rights, limitations of rights,
duties and obligations under the Guarantees of each of the Guarantors. 

                    Events
of Default. If an Event of Default with respect to the Notes shall have
occurred and be continuing, the principal of the Notes of this series may be
declared due and payable in the manner and with the effect provided in the
Indenture.

A-3

                    Maturity.
The Notes of this series are not subject to any sinking fund. The Notes of this
series will be redeemable at any time, at the option of the Company, in whole
or from time to time in part, upon not less than 30 nor more than 60 days’
prior notice, on any date prior to their maturity at a Redemption Price,
calculated pursuant to the Indenture, together with accrued interest thereon,
if any, to the Redemption Date (subject to the rights of holders of record on
the Regular Record Date that is prior to the Redemption Date to receive
interest on the relevant Interest Payment Date). In the case of any partial
redemption, selection of the Notes of this series for redemption will be made
by the Trustee by such methods, as the Trustee in its sole discretion shall
deem fair and appropriate. If any Note is to be redeemed in part only, the
notice of redemption relating to such Note shall state the portion of the
principal amount thereof to be redeemed. A new Note in principal amount equal
to the unredeemed portion thereof will be issued in the name of the Holder
thereof upon cancellation of this Note.

                    Redemption
upon a Change of Control Triggering Event. Upon the occurrence of a Change
of Control Triggering Event, the Company shall be required to make an offer to
repurchase the Notes on the terms set forth in the Indenture.

                    Defeasance
and Covenant Defeasance. The Indenture contains provisions for defeasance
at any time of (a) the entire indebtedness of the Company on this Note and (b)
certain restrictive covenants and the related Defaults and Events of Default,
upon compliance by the Company with certain conditions set forth therein, which
provisions apply to this Note. 

                    Modification
and Waivers; Obligations of the Company Absolute. The Indenture permits,
with certain exceptions as therein provided, the amendment thereof and the
modification of the rights and obligations of the Company and the rights of the
Holders of the Securities of each series. Such amendment may be effected under
the Indenture at any time by the Company, the Subsidiary Guarantors and the
Trustee with the consent of the Holders of not less than a majority in
aggregate principal amount of the Outstanding Notes of each series affected
thereby. The Indenture also contains provisions permitting the Holders of not
less than a majority in aggregate principal amount of the Securities at the
time Outstanding, on behalf of the Holders of all Outstanding Securities, to
waive compliance by the Company with certain provisions of the Indenture.
Furthermore, provisions in the Indenture permit the Holders of not less than a
majority in aggregate principal amount of the Outstanding Securities of
individual series to waive on behalf of all of the Holders of Securities of
such individual series certain past defaults under the Indenture and their
consequences. Any such consent or waiver shall be conclusive and binding upon
the Holder of this Note and upon all future Holders of this Note and of any
Note issued upon the registration of transfer hereof or in exchange hereof or
in lieu hereof, whether or not notation of such consent or waiver is made upon
this Note. 

                    No
reference herein to the Indenture and no provision of this Note or of the
Indenture shall alter or impair the obligation of the Company, which is
absolute and unconditional, to pay the principal of and interest on this Note
at the time, place, and rate, and in the coin or currency, herein prescribed.

                    Limitation
on Suits. As set forth in, and subject to, the provisions of the Indenture,
no Holder of any Note of this series will have any right to institute any
proceeding with respect to the Indenture or for any remedy thereunder, unless
such Holder shall have previously given to the Trustee written notice of a
continuing Event of Default with respect to this series, the Holders of not
less than 25% in principal amount of the Outstanding Notes of this series shall
have made written request, and offered reasonable indemnity, to the Trustee to
institute such proceedings as trustee, and the Trustee shall not have received
from the Holders of a majority in principal amount of the Outstanding Notes of
this series a direction inconsistent with such request and shall have failed to
institute such proceeding within

A-4

60 days; provided,
however, that such limitations do
not apply to a suit instituted by the Holder hereof for the enforcement of
payment of the principal of or interest on this Note on or after the respective
due dates expressed herein. 

                    Authorized
Denominations. The Notes of this series are issuable only in registered
form without coupons in denominations of $2,000 or any integral multiple of
$1,000 in excess thereof.

                    Registration
of Transfer or Exchange. As provided in the Indenture and subject to
certain limitations herein and therein set forth, the transfer of this Note is
registrable in the Security Register upon surrender of this Note for
registration of transfer at the office or agency of the Company in any place
where the principal of and interest on this Note are payable, duly endorsed by,
or accompanied by a written instrument of transfer in form satisfactory to the
Company and the Security Registrar duly executed by, the Holder hereof or his
attorney duly authorized in writing, and thereupon one or more new Notes, of
authorized denominations and for the same aggregate principal amount, will be
issued to the designated transferee or transferees. 

                    As
provided in the Indenture and subject to certain limitations herein and therein
set forth, the Notes are exchangeable for a like aggregate principal amount of
Notes of different authorized denominations, as requested by the Holders
surrendering the same.

                    [The
following paragraph applies only if the Note is a Global Note:

                    This
Note is a Global Security. If the Depository is at any time unwilling,
unable or ineligible to continue as depository and a successor depository is
not appointed by the Company within 90 days or an Event of Default under the
Indenture has occurred and is continuing, the Company will issue Securities in
certificated form in exchange for each Global Security. In addition, the
Company may at any time determine not to have Securities represented by a
Global Security and, in such event, will issue Securities in certificated form
in exchange in whole for the Global Security representing such Security. In any
such instance, an owner of a beneficial interest in a Global Security will be
entitled to physical delivery in certificated form of Securities equal in
principal amount to such beneficial interest and to have such Securities
registered in its name. Securities so issued in certificated form will be
issued in denominations of $2,000 or any amount in excess thereof which is an
integral multiple of $1,000 and will be issued in registered form only, without
coupons.

                    No
service charge shall be made for any such registration of transfer or exchange,
but the Company may require payment of a sum sufficient to cover any tax or
other governmental charge payable in connection therewith.

                    Prior
to due presentment of this Note for registration of transfer, the Company, the
Trustee and any agent of the Company or the Trustee may treat the Holder as the
owner hereof for all purposes, whether or not this Note be overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the
contrary.]

                    Defined
Terms. All terms used in this Note, which are defined in the Indenture and
are not otherwise defined herein, shall have the meanings assigned to them in
the Indenture.

                    Governing Law. This Note shall be governed
by and construed in accordance with the law of the State of New York.

A-5

                    Unless
the certificate of authentication hereon has been executed by the Trustee by
manual signature, this Note shall not be entitled to any benefit under the
Indenture or be valid or obligatory for any purpose.

A-6

                    IN
WITNESS WHEREOF, the Company has caused this instrument to be duly executed.

Dated: June 22, 2007

	
   

  	
   

  	
   

  
	
   

  	
  QUEST DIAGNOSTICS INCORPORATED

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

	
   

  	

	
   

  	
  Name: 

  
	
Attest:

  	
  Title:

  

	
   

  	
   

  	
   

  
	
  By:

  	
   

  	
   

  
	
   

  	
  

  	
   

  
	
  Name:

  	
   

  
	
  Title:

  	
   

  

A-7

TRUSTEE’S
CERTIFICATE OF AUTHENTICATION

                    This
is one of the Notes of the series designated and referred to in the
within-mentioned Indenture, as such is supplemented by the within-mentioned
Tenth Supplemental Indenture.

	
   

  	
   

  	
   

  
	
   

  	
  THE BANK OF NEW YORK

  
	
   

  	
  as Trustee

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
  

  
	
   

  	
  Vice President

  
	
   

  	
  Authorized Signatory

  

Dated: June 22, 2007

A-8

GUARANTEE OF THE
SUBSIDIARY GUARANTORS

                    FOR
VALUE RECEIVED, each of the Subsidiary Guarantors (as such term is defined in
the Indenture, as amended by the First Supplemental Indenture, the Second
Supplemental Indenture, the Third Supplemental Indenture, the Fourth
Supplemental Indenture, the Fifth Supplemental Indenture, the Sixth
Supplemental Indenture, the Seventh Supplemental Indenture, the Eighth
Supplemental Indenture, the Ninth Supplemental Indenture and the Tenth
Supplemental Indenture), hereby, jointly and severally, unconditionally
guarantees to the Holder of the Note upon which this Subsidiary Guarantee is
endorsed (the “Note”) and to the Trustee on behalf of the Holder, the prompt
payment of the principal of (and premium, if any, on) and interest (including,
in case of default, interest on principal and, to the extent permitted by
applicable law, on overdue interest and including any additional interest
required to be paid according to the terms of the Notes) on the Note, when due
(whether at Stated Maturity, upon Redemption, upon acceleration, upon tender
for repayment at the option of the Company), according to the terms hereof and
the terms of the Indenture (the “Guarantor Obligations”). This Guarantee is a guarantee
of payment and not of collection and is a continuing guarantee and shall apply
to all Guarantor Obligations whenever arising. 

                    Obligations
Unconditional and Absolute. The obligations of the Subsidiary Guarantors
hereunder are absolute and unconditional irrespective of the value,
genuineness, validity, regularity or enforceability of the Indenture or this
Note, to the fullest extent permitted by applicable law, irrespective of any
circumstance whatsoever which might otherwise constitute a legal or equitable
discharge or defense of a surety or guarantor. Each of the Subsidiary
Guarantors agrees that this Guarantee may be enforced by the Holder of this
Note without the necessity at any time of proceeding against the Company or any
other Person (including a co-guarantor) or to pursue any other remedy or
enforce any other right. Each of the Subsidiary Guarantors further agrees that
nothing contained herein shall prevent the Holder of this Note from suing on
this Note or the Indenture or from exercising any other rights available under
this Note and the Indenture, and the exercise of any of the aforesaid rights
and shall not constitute a discharge of any Subsidiary Guarantor’s obligations
hereunder and under the Indenture; it being the purpose and the intent of each
Subsidiary Guarantor that its obligations under this Note and under the
Indenture shall be absolute, independent and unconditional under any and all
circumstances. Neither any Subsidiary Guarantor’s obligations under this Guarantee
nor any remedy for the enforcement thereof shall be impaired, modified, changed
or released in any manner whatsoever by an impairment, modification, change,
release or limitation of the liability of the Company or by reason of the
bankruptcy or insolvency of the Company. Each Subsidiary Guarantor waives any
and all notice of the creation, renewal, extension or accrual of any of the
Guarantor Obligations or acceptance of this Guarantee. The Guarantor
Obligations, and any of them, shall conclusively be deemed to have been
created, contracted or incurred, or renewed, extended, amended or waived, in
reliance upon this Guarantee. 

                    Subrogation.
Each of the Subsidiary Guarantors shall be subrogated to all rights of the
Holder of the Note against the Company in respect of any amounts paid by such
Subsidiary Guarantor on account of the Note or the Indenture; provided, however, that such Subsidiary
Guarantor shall not be entitled to enforce or to receive any payments arising
out of, or based upon, such right of subrogation until the principal of (or
premium, if any, on) and interest on all Notes of this series shall have been
indefeasibly paid in full. 

                    Modifications.
Each Subsidiary Guarantor agrees that (a) the time or place of payment of the
Guarantor Obligations may be changed or extended, in whole or in part, to a
time certain or otherwise, and may be renewed or accelerated, in whole or in
part; (b) the Company and any other party liable for payment under the
Indenture or under the Note may be granted indulgences generally; (c) any of
the

A-9

provisions of this Note or the
Indenture may be modified, amended or waived; and (d) any party (including any
Subsidiary Guarantor) liable for the payment under this Note or under the
Indenture may be granted indulgences or be released; all without notice to or
further assent by such Subsidiary Guarantor, which shall remain bound thereon,
notwithstanding any such exchange, compromise, surrender, extension, renewal,
acceleration, modification, indulgence or release.

                    Waiver
of Rights. Each of the Subsidiary Guarantors hereby waives to the fullest
extent permitted by law: (a) notice of acceptance of this Guarantee by the
Holder of this Note; (b) presentment and demand for payment or performance of
any of the Guarantor Obligations; (c) protest and notice of dishonor or default
with respect to the Guarantor Obligations; (d) all other notices to which such
Subsidiary Guarantor might otherwise be entitled. 

                    Reinstatement.
The obligations of the Subsidiary Guarantors under this Note and under Article
Sixteen shall be automatically reinstated if and to the extent that for any
reason any payment by or on behalf of any Person in respect of the Guarantor
Obligations is rescinded or must otherwise be restored by any Holder of the
Notes of this series, whether as a result of any proceedings in bankruptcy or
reorganization or otherwise.

                    Remedies.
Each of the Subsidiary Guarantors further agrees, to the fullest extent that it
may lawfully do so, that as between each such Subsidiary Guarantor, on the one
hand, and the Holder and the Trustee, on the other hand, the maturity of the
obligations guaranteed hereby may be accelerated as provided in Article Five of
the Indenture for the purposes of this guarantee, notwithstanding any stay,
injunction or other prohibition extant under any applicable bankruptcy law
preventing such acceleration in respect of the obligations guaranteed hereby. 

                    Rights
of Contribution. The Subsidiary Guarantors, in connection with payments
made hereunder, shall have contribution rights against the other Subsidiary
Guarantors as permitted under applicable law. Such contribution rights shall be
subordinate and subject in right of payment to the obligations of the
Subsidiary Guarantors under this Note and no Subsidiary Guarantor shall
exercise such rights of contribution until all Guarantor Obligations have been
paid in full.

                    Limitation
of Guaranty. Notwithstanding any provision to the contrary contained herein
or in the Indenture, to the extent the obligations of any Subsidiary Guarantor
shall be adjudicated to be invalid or unenforceable for any reason (including,
without limitation, because of any applicable state or federal law relating to
fraudulent conveyances or transfers) then the obligations of the Subsidiary
Guarantors hereunder shall be limited to the maximum amount that is permissible
under applicable law (whether federal or state or otherwise and including,
without limitation, the Bankruptcy Code).

                    Release
of Guarantors. Each of the Subsidiary Guarantors hereby covenants that its
Subsidiary Guarantee will not be discharged except by complete performance of
its obligations contained in the Note, this Subsidiary Guarantee and pursuant
to the Indenture; provided,
however, that if (a) an
Subsidiary Guarantor does not guarantee any Indebtedness of the Company the
amount of which, when added together with any other outstanding Indebtedness of
the Company guaranteed by its Subsidiaries that are not Subsidiary Guarantors,
would exceed $50 million in the aggregate, excluding the Notes of this series,
and all outstanding Indebtedness of such Subsidiary Guarantor would have been
permitted to be incurred pursuant to Section 1011 of the Indenture measured at
the time of the release and discharge as described in this paragraph, (b) the
Notes of this series are defeased and discharged pursuant to Article Fourteen
of the Indenture, or (c) all or substantially all of the assets of such
Subsidiary Guarantor or all of the capital stock of such Subsidiary Guarantor
is sold (including by issuance, merger, consolidation or otherwise) by the
Company or any of its Subsidiaries, then in each case of (a), (b) or (c) above,
such Subsidiary Guarantor or the corporation acquiring such assets (in the
event of a sale or other disposition

A-10

of all or substantially all
of the assets or capital stock of such Subsidiary Guarantor) shall be automatically
and without any further action on the part of any party to the Indenture, and
upon notice to the Trustee, be fully released and discharged from all its
liabilities and obligations under or in respect of the Indenture and this
Subsidiary Guarantee of the Note, and promptly upon the request of the Company
and at the expense of the Company, the Trustee shall execute such documents and
take such other action as is reasonably requested by the Company to evidence
the release and discharge of such Guarantor from all such liabilities and
obligations and shall, if applicable, certify to the Company that such
Subsidiary Guarantor has no liabilities or obligations resulting from a demand
on such Subsidiary Guarantor’s Guarantee. 

                    Defined
Terms. All terms used in this Note, which are defined in the Indenture and
are not otherwise defined herein, shall have the meanings assigned to them in
the Indenture.

                    Governing
Law. This Subsidiary Guarantee shall be governed by and construed in
accordance with the law of the State of New York. 

                    Subject
to the next following paragraph, each Subsidiary Guarantor hereby certifies and
warrants that all acts, conditions and things required to be done and performed
and to have happened precedent to the creation and issuance of this Subsidiary
Guarantee and to constitute the same valid obligation of each Subsidiary
Guarantor have been done and performed and have happened in due compliance with
all applicable laws. 

(Remainder of page
intentionally left blank.)

A-11

                    This
Subsidiary Guarantee shall not be valid or become obligatory for any purpose
until the certificate of authentication on the Note upon which this Subsidiary
Guarantee is endorsed has been signed by the Trustee under the Indenture
referred to in this Note.

Dated: June 22, 2007

	
   

  	
   

  
	
   

  	
  QUEST DIAGNOSTICS HOLDINGS INCORPORATED

  
	
   

  	
  QUEST DIAGNOSTICS CLINICAL LABORATORIES, INC.

  
	
   

  	
  QUEST DIAGNOSTICS NICHOLS INSTITUTE

  
	
   

  	
  QUEST DIAGNOSTICS INCORPORATED (NV)

  
	
   

  	
  QUEST DIAGNOSTICS INCORPORATED (MD)

  
	
   

  	
  QUEST DIAGNOSTICS LLC (IL)

  
	
   

  	
  QUEST DIAGNOSTICS LLC (CT)

  
	
   

  	
  QUEST DIAGNOSTICS LLC (MA)

  
	
   

  	
  QUEST DIAGNOSTICS INCORPORATED (MI)

  
	
   

  	
  QUEST DIAGNOSTICS OF PENNSYLVANIA INC.

  
	
   

  	
  AML INC.

  
	
   

  	
  AMERICAN MEDICAL LABORATORIES 

  
	
   

  	
  INCORPORATED

  
	
   

  	
  APL PROPERTIES LIMITED LIABILITY COMPANY

  
	
   

  	
  METWEST INC.

  
	
   

  	
  QUEST DIAGNOSTICS NICHOLS INSTITUTE, INC.

  
	
   

  	
  DPD HOLDINGS, INC.

  
	
   

  	
  DIAGNOSTIC REFERENCE SERVICES INC.

  
	
   

  	
  PATHOLOGY BUILDING PARTNERSHIP

  
	
   

  	
  UNILAB CORPORATION

  
	
   

  	
  FNA CLINICS OF AMERICA, INC. 

  
	
   

  	
  LABONE, INC

  
	
   

  	
  EXAMONE WORLD WIDE, INC.

  
	
   

  	
  EXAMONE WORLD WIDE OF NJ, INC.

  
	
   

  	
  CENTRAL PLAINS HOLDINGS, INC.

  
	
   

  	
  CENTRAL PLAINS LABORATORIES,
  LLC

  
	
   

  	
  LABONE OF OHIO, INC.

  
	
   

  	
  OSBORN GROUP INC.

  
	
   

  	
  SYSTEMATIC BUSINESS SERVICES, INC.

  

	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  

  
	
   

  	
                      Name:

  
	
   

  	
                      Title:

  

A-12

	
   

  	
   

  	
   

  
	
   

  	
  NICHOLS INSTITUTE DIAGNOSTICS

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
  

  
	
   

  	
                      Name:

  
	
   

  	
                      Title:
  

  
	
   

  	
   

  
	
   

  	
  FOCUS TECHNOLOGIES HOLDING COMPANY

  FOCUS DIAGNOSTICS, INC.

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
  

  
	
   

  	
                      Name:

  
	
   

  	
                      Title:
  

  

A-13

	
   

  	
   

  
	
   

  	
  AMERIPATH, INC.

  
	
   

  	
  AMERIPATH CONSOLIDATED LABS, INC.

  
	
   

  	
  AMERIPATH FLORIDA, LLC 

  
	
   

  	
  AMERIPATH HOSPITAL SERVICES FLORIDA, LLC 

  
	
   

  	
  AMERIPATH INDIANA, LLC 

  
	
   

  	
  AMERIPATH KENTUCKY, INC. 

  
	
   

  	
  AMERIPATH MARKETING USA, INC. 

  
	
   

  	
  AMERIPATH MICHIGAN, INC.

  
	
   

  	
   AMERIPATH
  MISSISSIPPI. INC.

  
	
   

  	
   AMERIPATH
  NEW YORK, LLC 

  
	
   

  	
  AMERIPATH NORTH CAROLINA, INC. 

  
	
   

  	
  AMERIPATH OHIO, INC. 

  
	
   

  	
  AMERIPATH PENNSYLVANIA, LLC 

  
	
   

  	
  AMERIPATH PHILADELPHIA, INC. 

  
	
   

  	
  AMERIPATH SC, INC. 

  
	
   

  	
  AMERIPATH TEXAS, LP. 

  
	
   

  	
  AMERIPATH YOUNGSTOWN LABS, INC. 

  
	
   

  	
  AMERIPATH WISCONSIN, LLC 

  
	
   

  	
  AMERIPATH, LLC 

  
	
   

  	
  API NO. 2, LLC

  
	
   

  	
  ANATOMIC PATHOLOGY SERVICES, INC. 

  
	
   

  	
  ARIZONA PATHOLOGY GROUP, INC. 

  
	
   

  	
  DERMATOPATHOLOGY SERVICES, INC. 

  
	
   

  	
  DIAGNOSTIC PATHOLOGY MANAGEMENT SERVICES, LLC

  
	
   

  	
  KAILASH B. SHARMA, M.D., INC.

  
	
   

  	
  OCMULGEE MEDICAL PATHOLOGY ASSOCIATION INC.

  
	
   

  	
  O’QUINN MEDICAL PATHOLOGY ASSOCIATION, LLC

  
	
   

  	
  PCA OF DENVER, INC. 

  
	
   

  	
  PCA OF NASHVILLE, INC. 

  
	
   

  	
  PETER G. KLACSMANN M.D., INC. 

  
	
   

  	
  REGIONAL PATHOLOGY CONSULTANTS, LLC 

  
	
   

  	
  ROCKY MOUNTAIN PATHOLOGY, LLC

  
	
   

  	
  SHARON G. DASPIT, M.D., INC. 

  
	
   

  	
  SHOALS PATHOLOGY
  ASSOCIATES, INC.

  
	
   

  	
  SPECIALTY LABORATORIES, INC.

  
	
   

  	
  STRIGEN, INC. 

  
	
   

  	
  TID ACQUISITION CORP. 

  
	
   

  	
   

  

	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  

  
	
   

  	
                      Name:

  
	
   

  	
                      Title:

  

A-14

	
   

  	
   

  	
   

  
	
   

  	
  ENTERIX INC.

  HEMOCUE, INC.

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  

  
	
   

  	
                      Name:

  
	
   

  	
                      Title:

  
	
   

  	
   

  
	
   

  	
  QUEST DIAGNOSTICS INVESTMENTS INCORPORATED

  QUEST DIAGNOSTICS FINANCE INCORPORATED

  
	
   

  	
   

  
	
   

  	
  By:

  	
   

  
	
   

  	
   

  	
  

  
	
   

  	
                      Name:

  
	
   

  	
                      Title:

  

A-15

EXHIBIT B

Form of 6.95% Senior Note due 2037

                    [The
following legends apply only if the Note is a Global Note:

                    THIS
NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED
TO AND IS REGISTERED IN THE NAME OF A DEPOSITORY OR A NOMINEE THEREOF. THIS
NOTE MAY NOT BE EXCHANGED IN WHOLE OR IN PART FOR A NOTE REGISTERED, AND NO
TRANSFER OF THIS NOTE IN WHOLE OR IN PART MAY BE REGISTERED, IN THE NAME OF ANY
PERSON OTHER THAN SUCH DEPOSITORY OR ITS NOMINEE EXCEPT IN THE LIMITED
CIRCUMSTANCES DESCRIBED IN THE INDENTURE.

                    UNLESS
THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY
TRUST COMPANY TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE
OR PAYMENT AND SUCH CERTIFICATE ISSUED IN EXCHANGE FOR THIS CERTIFICATE IS
REGISTERED IN THE NAME OF CEDE & CO., OR SUCH OTHER NAME AS REQUESTED BY AN
AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY, ANY TRANSFER, PLEDGE OR OTHER USE
HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL, SINCE THE
REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.]

B-1

QUEST DIAGNOSTICS INCORPORATED

6.95% Senior Note due 2037

Unconditionally guaranteed as to payment of

principal of and interest by

the Subsidiary Guarantors

	
 

	
 

	
 

	
No. 0 (Specimen)

	
 

	
$425,000,000

	
 

	
 

	
 

	
CUSIP: 74834L AN0

	
 

	
 

                    Quest
Diagnostics Incorporated, a Delaware corporation (herein called the “Company,”
which term includes any successor Person under the Indenture hereinafter
referred to), for value received, hereby promises to pay to Cede & Co., or
registered assigns, the principal sum of $425,000,000 on July 1, 2037 (the
“Stated Maturity”) (except to the extent redeemed or repaid prior to the Stated
Maturity) and to pay interest thereon from June 22, 2007 or from the most
recent Interest Payment Date to which interest has been paid or duly provided
for semi-annually at the rate of 6.95% per annum, on July 1 and January 1,
commencing with January 1, 2008, on the Stated Maturity and on any Redemption Date
(each such date, an “Interest Payment Date”) until the principal hereof is paid
or made available for payment. 

                    Payment
of Interest. The interest so payable, and punctually paid or made available
for payment, on any Interest Payment Date, will, as provided in the Indenture,
be paid, in immediately available funds, to the Person in whose name this Note
(or one or more Predecessor Securities) is registered at the close of business
June 15 or December 15 (whether or not a Business Day, as defined in the
Indenture), as the case may be, next preceding such Interest Payment Date (the
“Regular Record Date”). Any such interest not punctually paid or duly provided
for (“Defaulted Interest”) will forthwith cease to be payable to the Holder on
such Regular Record Date, and such Defaulted Interest, may be paid to the
Person in whose name this Note (or one or more Predecessor Securities) is
registered at the close of business on a special record date (the “Special
Record Date”) for the payment of such Defaulted Interest to be fixed by the
Trustee, notice whereof shall be given to Holders of Notes not less than ten
days prior to such Special Record Date, or may be paid at any time in any other
lawful manner not inconsistent with requirements of any securities exchange on
which the Notes may be listed, and upon such notice as may be required by such
exchange, all as more fully provided in said Indenture. 

                    Place
of Payment. Payment of interest on this Note will be made at the Corporate
Trust Office of the Trustee or such other office or agency of the Company as
may be designated for such purpose, in such coin or currency of the United
States of America as at the time of payment is legal tender for payment of
public and private debts; provided, however,
that each installment of interest and payment of principal on this Notes may at
the Company’s option be paid in immediately available funds by transfer to an
account maintained by the payee located in the United States. Payment of the principal
of this Note on the Stated Maturity will be made against presentation of this
Note at the office or agency of the Company maintained for that purpose in the
Borough of Manhattan, The City of New York, in such coin or currency of the
United States of America as at the time of payment is legal tender for the
payment of public and private debts. 

                    Time
of Payment. In any case where any Interest Payment Date, Redemption Date,
Stated Maturity shall not be a Business Day at any Place of Payment, then
(notwithstanding any other provision of the Indenture or this Note), payment of
principal or interest, if any, need not be made at such Place of Payment on
such date, but may be made on the next succeeding Business Day at such Place of
Payment with the same force and effect as if made on the Interest Payment Date,
Redemption Date, or at

B-2

Stated
Maturity; provided that no interest shall accrue on the amount so
payable for the period from and after such Interest Payment Date, Redemption Date,
Repayment Date, or Stated Maturity, as the case may be.

                    Legends.
The statements set forth in the restrictive legends above are an integral part
of the terms of this Note and by acceptance hereof each Holder of this Note
agrees to be subject to and bound by the terms and provisions set forth in such
legend. 

                    General.
This Note is one of a duly authorized issue of securities (herein called the
“Securities”) of the Company, issued and to be issued in one or more series
under an indenture, dated as of June 27, 2001 (the “Base Indenture”), between
the Company and The Bank of New York, Trustee (herein called the “Trustee”,
which term includes any successor trustee under the Indenture with respect to a
series of which this Note is a part), to which Base Indenture and all
indentures supplemental thereto, including the supplemental indenture dated
June 22, 2007 (the “Supplemental Indenture”), reference is hereby made for a
statement of the respective rights, limitations of rights, duties and
immunities thereunder of the Company, the Trustee and the Holders of the
Securities, and of the terms upon which the Securities are, and are to be,
authenticated and delivered. This Note is one of a duly authorized series of
Securities designated as “6.95% Senior Notes due 2037” (collectively, the
“Notes”), initially limited in aggregate principal amount to $425,000,000.

                    Further
Issuance. The Company may from time to time, without the consent of the
Holders of Notes of this series, issue additional Notes (the “Additional
Notes”) of this series having the same ranking and the same interest rate,
maturity and other terms as the Notes of this series. Any Additional Notes of
this series and the Notes of this series will constitute a single series under
the Indenture and all references to the Notes of this series shall include the
Additional Notes unless the context otherwise requires. 

                    
[The
following paragraph applies only if the Note is a Global Note:

                    Book-Entry.
This Note is a Global Note representing $425,000,000 of the Notes. This Note is
a “book entry” Note and is being registered in the name of Cede & Co. as
nominee of The Depository Trust Company (the “Depository “), a clearing agency.
Subject to the terms of the Indenture, this Note will be held by a clearing
agency or its nominee, and beneficial interest will be held by beneficial
owners through the book-entry facilities of such clearing agency or its nominee
in minimum denominations of $2,000 and integral multiples of $1,000 in excess
thereof. As long as this Note is registered in the name of the Depository or
its nominee, the Trustee will make payments of principal and interest on this
Note by wire transfer of immediately available funds to the Depository or its
nominee. Notwithstanding the above, the final payment on this Note will be made
after due notice by the Trustee of the pendency of such payment and only upon
presentation and surrender of this Note at its Corporate Trust Office or such
other offices or agencies appointed by the Trustee for that purpose and such
other locations provided in the Indenture.]

                    Guarantees.
This Note is entitled to the benefits of the Subsidiary Guarantees by each of
the Subsidiary Guarantors of the due and punctual payment and performance of
the Guarantor Obligations made in favor of the Trustee for the benefit of the
Holder of this Note. Reference is hereby made to Article Sixteen of the
Indenture for a statement of the respective rights, limitations of rights,
duties and obligations under the Guarantees of each of the Guarantors. 

                    Events
of Default. If an Event of Default with respect to the Notes shall have
occurred and be continuing, the principal of the Notes of this series may be
declared due and payable in the manner and with the effect provided in the
Indenture.

B-3

                    Maturity.
The Notes of this series are not subject to any sinking fund. The Notes of this
series will be redeemable at any time, at the option of the Company, in whole
or from time to time in part, upon not less than 30 nor more than 60 days’
prior notice, on any date prior to their maturity at a Redemption Price,
calculated pursuant to the Indenture, together with accrued interest thereon,
if any, to the Redemption Date (subject to the rights of holders of record on
the Regular Record Date that is prior to the Redemption Date to receive
interest on the relevant Interest Payment Date). In the case of any partial
redemption, selection of the Notes of this series for redemption will be made
by the Trustee by such methods, as the Trustee in its sole discretion shall
deem fair and appropriate. If any Note is to be redeemed in part only, the
notice of redemption relating to such Note shall state the portion of the
principal amount thereof to be redeemed. A new Note in principal amount equal
to the unredeemed portion thereof will be issued in the name of the Holder
thereof upon cancellation of this Note.

                    Redemption
upon a Change of Control Triggering Event. Upon the occurrence of a Change
of Control Triggering Event, the Company shall be required to make an offer to
repurchase the Notes on the terms set forth in the Indenture.

                    Defeasance
and Covenant Defeasance. The Indenture contains provisions for defeasance
at any time of (a) the entire indebtedness of the Company on this Note and (b)
certain restrictive covenants and the related Defaults and Events of Default,
upon compliance by the Company with certain conditions set forth therein, which
provisions apply to this Note. 

                    Modification
and Waivers; Obligations of the Company Absolute. The Indenture permits,
with certain exceptions as therein provided, the amendment thereof and the
modification of the rights and obligations of the Company and the rights of the
Holders of the Securities of each series. Such amendment may be effected under
the Indenture at any time by the Company, the Subsidiary Guarantors and the
Trustee with the consent of the Holders of not less than a majority in
aggregate principal amount of the Outstanding Notes of each series affected
thereby. The Indenture also contains provisions permitting the Holders of not
less than a majority in aggregate principal amount of the Securities at the
time Outstanding, on behalf of the Holders of all Outstanding Securities, to
waive compliance by the Company with certain provisions of the Indenture.
Furthermore, provisions in the Indenture permit the Holders of not less than a
majority in aggregate principal amount of the Outstanding Securities of
individual series to waive on behalf of all of the Holders of Securities of
such individual series certain past defaults under the Indenture and their
consequences. Any such consent or waiver shall be conclusive and binding upon
the Holder of this Note and upon all future Holders of this Note and of any
Note issued upon the registration of transfer hereof or in exchange hereof or
in lieu hereof, whether or not notation of such consent or waiver is made upon
this Note. 

                    No
reference herein to the Indenture and no provision of this Note or of the
Indenture shall alter or impair the obligation of the Company, which is
absolute and unconditional, to pay the principal of and interest on this Note
at the time, place, and rate, and in the coin or currency, herein prescribed.

                    Limitation
on Suits. As set forth in, and subject to, the provisions of the Indenture,
no Holder of any Note of this series will have any right to institute any
proceeding with respect to the Indenture or for any remedy thereunder, unless
such Holder shall have previously given to the Trustee written notice of a
continuing Event of Default with respect to this series, the Holders of not
less than 25% in principal amount of the Outstanding Notes of this series shall
have made written request, and offered reasonable indemnity, to the Trustee to
institute such proceedings as trustee, and the Trustee shall not have received
from the Holders of a majority in principal amount of the Outstanding Notes of
this series a direction inconsistent with such request and shall have failed to
institute such proceeding within

B-4

60 days; provided, however,
that such limitations do not apply to a suit instituted by the Holder hereof
for the enforcement of payment of the principal of or interest on this Note on
or after the respective due dates expressed herein. 

                    Authorized
Denominations. The Notes of this series are issuable only in registered
form without coupons in denominations of $2,000 or any integral multiple of
$1,000 in excess thereof.

                    Registration
of Transfer or Exchange. As provided in the Indenture and subject to
certain limitations herein and therein set forth, the transfer of this Note is
registrable in the Security Register upon surrender of this Note for
registration of transfer at the office or agency of the Company in any place
where the principal of and interest on this Note are payable, duly endorsed by,
or accompanied by a written instrument of transfer in form satisfactory to the
Company and the Security Registrar duly executed by, the Holder hereof or his
attorney duly authorized in writing, and thereupon one or more new Notes, of
authorized denominations and for the same aggregate principal amount, will be
issued to the designated transferee or transferees. 

                    As
provided in the Indenture and subject to certain limitations herein and therein
set forth, the Notes are exchangeable for a like aggregate principal amount of
Notes of different authorized denominations, as requested by the Holders
surrendering the same.

                    
[The
following paragraph applies only if the Note is a Global Note:

                    This
Note is a Global Security. If the Depository is at any time unwilling,
unable or ineligible to continue as depository and a successor depository is
not appointed by the Company within 90 days or an Event of Default under the
Indenture has occurred and is continuing, the Company will issue Securities in
certificated form in exchange for each Global Security. In addition, the
Company may at any time determine not to have Securities represented by a
Global Security and, in such event, will issue Securities in certificated form
in exchange in whole for the Global Security representing such Security. In any
such instance, an owner of a beneficial interest in a Global Security will be
entitled to physical delivery in certificated form of Securities equal in principal
amount to such beneficial interest and to have such Securities registered in
its name. Securities so issued in certificated form will be issued in
denominations of $2,000 or any amount in excess thereof which is an integral
multiple of $1,000 and will be issued in registered form only, without coupons.

                    No
service charge shall be made for any such registration of transfer or exchange,
but the Company may require payment of a sum sufficient to cover any tax or
other governmental charge payable in connection therewith.

                    Prior
to due presentment of this Note for registration of transfer, the Company, the
Trustee and any agent of the Company or the Trustee may treat the Holder as the
owner hereof for all purposes, whether or not this Note be overdue, and neither
the Company, the Trustee nor any such agent shall be affected by notice to the
contrary.]

                    Defined
Terms. All terms used in this Note, which are defined in the Indenture and
are not otherwise defined herein, shall have the meanings assigned to them in
the Indenture.

                    Governing
Law. This Note shall be governed by and construed in
accordance with the law of the State of New York.

B-5

                    Unless
the certificate of authentication hereon has been executed by the Trustee by
manual signature, this Note shall not be entitled to any benefit under the
Indenture or be valid or obligatory for any purpose.

B-6

                    IN
WITNESS WHEREOF, the Company has caused this instrument to be duly executed.

Dated: June
22, 2007

	
 

	
 

	
 

	
 

	
 

	
 

	
 

	
QUEST
  DIAGNOSTICS INCORPORATED

	
 

	
 

	
 

	
 

	
 

	
By: 

	
 

	
 

	
 

	
 

	

	
 

	
 

	
Name: 

	
Attest:

	
 

	
Title:

	
 

	
 

	
 

	
By: 

	
 

	
 

	
 

	

	
 

	
 

	
 

	
 

	
 

	
Name: Leo C.
  Farrenkopf

	
 

	
 

	
Title:  Assistant
  General Counsel
           and
  Corporate Secretary

	
 

	
	
	

B-7

TRUSTEE’S CERTIFICATE OF AUTHENTICATION

                    This
is one of the Notes of the series designated and referred to in the
within-mentioned Indenture, as such is supplemented by the within-mentioned
Tenth Supplemental Indenture.

	
 

	
 

	
 

	
 

	
THE BANK OF
  NEW YORK

	
 

	
as Trustee

	
 

	
 

	
 

	
By: 

	
 

	
 

	

	
 

	
Vice
  President

	
 

	
Authorized
  Signatory

	
 

	
 

	
Dated: June
  22, 2007

	
 

B-8

GUARANTEE OF THE SUBSIDIARY GUARANTORS

                    FOR
VALUE RECEIVED, each of the Subsidiary Guarantors (as such term is defined in
the Indenture, as amended by the First Supplemental Indenture, the Second
Supplemental Indenture, the Third Supplemental Indenture, the Fourth
Supplemental Indenture, the Fifth Supplemental Indenture, the Sixth
Supplemental Indenture, the Seventh Supplemental Indenture, the Eighth
Supplemental Indenture, the Ninth Supplemental Indenture and the Tenth
Supplemental Indenture), hereby, jointly and severally, unconditionally
guarantees to the Holder of the Note upon which this Subsidiary Guarantee is
endorsed (the “Note”) and to the Trustee on behalf of the Holder, the prompt
payment of the principal of (and premium, if any, on) and interest (including,
in case of default, interest on principal and, to the extent permitted by
applicable law, on overdue interest and including any additional interest
required to be paid according to the terms of the Notes) on the Note, when due
(whether at Stated Maturity, upon Redemption, upon acceleration, upon tender
for repayment at the option of the Company), according to the terms hereof and
the terms of the Indenture (the “Guarantor Obligations”). This Guarantee is a
guarantee of payment and not of collection and is a continuing guarantee and
shall apply to all Guarantor Obligations whenever arising. 

                    Obligations
Unconditional and Absolute. The obligations of the Subsidiary Guarantors
hereunder are absolute and unconditional irrespective of the value,
genuineness, validity, regularity or enforceability of the Indenture or this
Note, to the fullest extent permitted by applicable law, irrespective of any
circumstance whatsoever which might otherwise constitute a legal or equitable
discharge or defense of a surety or guarantor. Each of the Subsidiary
Guarantors agrees that this Guarantee may be enforced by the Holder of this
Note without the necessity at any time of proceeding against the Company or any
other Person (including a co-guarantor) or to pursue any other remedy or
enforce any other right. Each of the Subsidiary Guarantors further agrees that
nothing contained herein shall prevent the Holder of this Note from suing on
this Note or the Indenture or from exercising any other rights available under
this Note and the Indenture, and the exercise of any of the aforesaid rights
and shall not constitute a discharge of any Subsidiary Guarantor’s obligations
hereunder and under the Indenture; it being the purpose and the intent of each
Subsidiary Guarantor that its obligations under this Note and under the
Indenture shall be absolute, independent and unconditional under any and all
circumstances. Neither any Subsidiary Guarantor’s obligations under this
Guarantee nor any remedy for the enforcement thereof shall be impaired,
modified, changed or released in any manner whatsoever by an impairment,
modification, change, release or limitation of the liability of the Company or
by reason of the bankruptcy or insolvency of the Company. Each Subsidiary
Guarantor waives any and all notice of the creation, renewal, extension or
accrual of any of the Guarantor Obligations or acceptance of this Guarantee.
The Guarantor Obligations, and any of them, shall conclusively be deemed to
have been created, contracted or incurred, or renewed, extended, amended or
waived, in reliance upon this Guarantee. 

                    Subrogation.
Each of the Subsidiary Guarantors shall be subrogated to all rights of the
Holder of the Note against the Company in respect of any amounts paid by such
Subsidiary Guarantor on account of the Note or the Indenture; provided, however, that such Subsidiary
Guarantor shall not be entitled to enforce or to receive any payments arising
out of, or based upon, such right of subrogation until the principal of (or
premium, if any, on) and interest on all Notes of this series shall have been
indefeasibly paid in full. 

                    Modifications.
Each Subsidiary Guarantor agrees that (a) the time or place of
payment of the Guarantor Obligations may be changed or extended, in whole or in
part, to a time certain or otherwise, and may be renewed or accelerated, in
whole or in part; (b) the Company and any other party liable for payment under
the Indenture or under the Note may be granted indulgences generally; (c) any
of the

B-9

provisions of this Note or the Indenture may be modified, amended or
waived; and (d) any party (including any Subsidiary Guarantor) liable for the
payment under this Note or under the Indenture may be granted indulgences or be
released; all without notice to or further assent by such Subsidiary Guarantor,
which shall remain bound thereon, notwithstanding any such exchange,
compromise, surrender, extension, renewal, acceleration, modification,
indulgence or release.

                    Waiver
of Rights. Each of the Subsidiary Guarantors hereby waives to the fullest
extent permitted by law: (a) notice of acceptance of this Guarantee by the
Holder of this Note; (b) presentment and demand for payment or performance of
any of the Guarantor Obligations; (c) protest and notice of dishonor or default
with respect to the Guarantor Obligations; (d) all other notices to which such
Subsidiary Guarantor might otherwise be entitled. 

                    Reinstatement.
The obligations of the Subsidiary Guarantors under this Note and under Article
Sixteen shall be automatically reinstated if and to the extent that for any
reason any payment by or on behalf of any Person in respect of the Guarantor
Obligations is rescinded or must otherwise be restored by any Holder of the
Notes of this series, whether as a result of any proceedings in bankruptcy or
reorganization or otherwise.

                    Remedies.
Each of the Subsidiary Guarantors further agrees, to the fullest extent that it
may lawfully do so, that as between each such Subsidiary Guarantor, on the one
hand, and the Holder and the Trustee, on the other hand, the maturity of the
obligations guaranteed hereby may be accelerated as provided in Article Five of
the Indenture for the purposes of this guarantee, notwithstanding any stay,
injunction or other prohibition extant under any applicable bankruptcy law
preventing such acceleration in respect of the obligations guaranteed hereby. 

                    Rights
of Contribution. The Subsidiary Guarantors, in connection with payments
made hereunder, shall have contribution rights against the other Subsidiary
Guarantors as permitted under applicable law. Such contribution rights shall be
subordinate and subject in right of payment to the obligations of the
Subsidiary Guarantors under this Note and no Subsidiary Guarantor shall
exercise such rights of contribution until all Guarantor Obligations have been
paid in full.

                    Limitation
of Guaranty. Notwithstanding any provision to the
contrary contained herein or in the Indenture, to the extent the obligations of
any Subsidiary Guarantor shall be adjudicated to be invalid or unenforceable
for any reason (including, without limitation, because of any applicable state
or federal law relating to fraudulent conveyances or transfers) then the
obligations of the Subsidiary Guarantors hereunder shall be limited to the
maximum amount that is permissible under applicable law (whether federal or
state or otherwise and including, without limitation, the Bankruptcy Code).

                    Release
of Guarantors. Each of the Subsidiary Guarantors hereby covenants that its
Subsidiary Guarantee will not be discharged except by complete performance of
its obligations contained in the Note, this Subsidiary Guarantee and pursuant
to the Indenture; provided,
however, that if (a) an
Subsidiary Guarantor does not guarantee any Indebtedness of the Company the
amount of which, when added together with any other outstanding Indebtedness of
the Company guaranteed by its Subsidiaries that are not Subsidiary Guarantors,
would exceed $50 million in the aggregate, excluding the Notes of this series,
and all outstanding Indebtedness of such Subsidiary Guarantor would have been
permitted to be incurred pursuant to Section 1011 of the Indenture measured at
the time of the release and discharge as described in this paragraph, (b) the
Notes of this series are defeased and discharged pursuant to Article Fourteen
of the Indenture, or (c) all or substantially all of the assets of such
Subsidiary Guarantor or all of the capital stock of such Subsidiary Guarantor
is sold (including by issuance, merger, consolidation or otherwise) by the
Company or any of its Subsidiaries, then in each case of (a), (b) or (c) above,
such Subsidiary Guarantor or the corporation acquiring such assets (in the
event of a sale or other disposition

B-10

of all or substantially all
of the assets or capital stock of such Subsidiary Guarantor) shall be
automatically and without any further action on the part of any party to the
Indenture, and upon notice to the Trustee, be fully released and discharged
from all its liabilities and obligations under or in respect of the Indenture
and this Subsidiary Guarantee of the Note, and promptly upon the request of the
Company and at the expense of the Company, the Trustee shall execute such
documents and take such other action as is reasonably requested by the Company
to evidence the release and discharge of such Guarantor from all such
liabilities and obligations and shall, if applicable, certify to the Company
that such Subsidiary Guarantor has no liabilities or obligations resulting from
a demand on such Subsidiary Guarantor’s Guarantee. 

                    Defined
Terms. All terms used in this Note, which are defined in the Indenture and
are not otherwise defined herein, shall have the meanings assigned to them in
the Indenture.

                    Governing
Law. This Subsidiary Guarantee shall be governed by and
construed in accordance with the law of the State of New York.

                    Subject
to the next following paragraph, each Subsidiary Guarantor hereby certifies and
warrants that all acts, conditions and things required to be done and performed
and to have happened precedent to the creation and issuance of this Subsidiary
Guarantee and to constitute the same valid obligation of each Subsidiary
Guarantor have been done and performed and have happened in due compliance with
all applicable laws. 

(Remainder of page intentionally left blank.)

B-11

                    This
Subsidiary Guarantee shall not be valid or become obligatory for any purpose
until the certificate of authentication on the Note upon which this Subsidiary
Guarantee is endorsed has been signed by the Trustee under the Indenture
referred to in this Note.

Dated: June
22, 2007

	
 

	
 

	
 

	
 

	
 

	
QUEST
  DIAGNOSTICS HOLDINGS INCORPORATED

	
 

	
QUEST
  DIAGNOSTICS CLINICAL LABORATORIES, INC.

	
 

	
QUEST
  DIAGNOSTICS NICHOLS INSTITUTE

	
 

	
QUEST
  DIAGNOSTICS INCORPORATED (NV)

	
 

	
QUEST
  DIAGNOSTICS INCORPORATED (MD)

	
 

	
QUEST
  DIAGNOSTICS LLC (IL)

	
 

	
QUEST
  DIAGNOSTICS LLC (CT)

	
 

	
QUEST DIAGNOSTICS LLC (MA)

	
 

	
QUEST
  DIAGNOSTICS INCORPORATED (MI)

	
 

	
QUEST
  DIAGNOSTICS OF PENNSYLVANIA INC.

	
 

	
AML INC.

	
 

	
AMERICAN
  MEDICAL LABORATORIES INCORPORATED

	
 

	
APL
  PROPERTIES LIMITED LIABILITY COMPANY

	
 

	
METWEST INC.

	
 

	
QUEST
  DIAGNOSTICS NICHOLS INSTITUTE, INC.

	
 

	
DPD
  HOLDINGS, INC.

	
 

	
DIAGNOSTIC
  REFERENCE SERVICES INC.

	
 

	
PATHOLOGY
  BUILDING PARTNERSHIP

	
 

	
UNILAB
  CORPORATION

	
 

	
FNA CLINICS
  OF AMERICA, INC. 

	
 

	
LABONE, INC

	
 

	
EXAMONE
  WORLD WIDE, INC.

	
 

	
EXAMONE
  WORLD WIDE OF NJ, INC.

	
 

	
CENTRAL
  PLAINS HOLDINGS, INC.

	
 

	
CENTRAL PLAINS LABORATORIES, LLC

	
 

	
LABONE OF
  OHIO, INC.

	
 

	
OSBORN GROUP
  INC.

	
 

	
SYSTEMATIC
  BUSINESS SERVICES, INC.

	
 

	
 

	
 

	
By: 

	
 

	
 

	
 

	
 

	

	
 

	
 

	
          Name:

	
 

	
 

	
 

	
          Title:

	
 

	
 

	
 

B-12

	
 

	
 

	
 

	
 

	
NICHOLS
  INSTITUTE DIAGNOSTICS

	
 

	
 

	
 

	
By: 

	
 

	
 

	

	
 

	
 

	
          Name:

	
 

	
 

	
          Title:

	
 

	
 

	
 

	
 

	
FOCUS
  TECHNOLOGIES HOLDING COMPANY
FOCUS DIAGNOSTICS, INC.

	
 

	
 

	
 

	
By: 

	
 

	
 

	

	
 

	
 

	
          Name:

	
 

	
 

	
          Title:

B-13

	
 

	
 

	
 

	
 

	
AMERIPATH,
  INC.

	
 

	
AMERIPATH
  CONSOLIDATED LABS, INC.

	
 

	
AMERIPATH
  FLORIDA, LLC

	
 

	
AMERIPATH
  HOSPITAL SERVICES FLORIDA, LLC

	
 

	
AMERIPATH
  INDIANA, LLC

	
 

	
AMERIPATH
  KENTUCKY, INC.

	
 

	
AMERIPATH
  MARKETING USA, INC.

	
 

	
AMERIPATH
  MICHIGAN, INC.

	
 

	
AMERIPATH
  MISSISSIPPI. INC.

	
 

	
AMERIPATH
  NEW YORK, LLC

	
 

	
AMERIPATH
  NORTH CAROLINA, INC.

	
 

	
AMERIPATH
  OHIO, INC.

	
 

	
AMERIPATH
  PENNSYLVANIA, LLC

	
 

	
AMERIPATH
  PHILADELPHIA, INC.

	
 

	
AMERIPATH
  SC, INC.

	
 

	
AMERIPATH
  TEXAS, LP.

	
 

	
AMERIPATH
  YOUNGSTOWN LABS, INC.

	
 

	
AMERIPATH
  WISCONSIN, LLC

	
 

	
AMERIPATH,
  LLC

	
 

	
API NO. 2,
  LLC

	
 

	
ANATOMIC
  PATHOLOGY SERVICES, INC. 

	
 

	
ARIZONA
  PATHOLOGY GROUP, INC.

	
 

	
DERMATOPATHOLOGY
  SERVICES, INC.

	
 

	
DIAGNOSTIC
  PATHOLOGY MANAGEMENT SERVICES, LLC

	
 

	
KAILASH B.
  SHARMA, M.D., INC.

	
 

	
OCMULGEE
  MEDICAL PATHOLOGY ASSOCIATION INC.

	
 

	
O’QUINN
  MEDICAL PATHOLOGY ASSOCIATION, LLC

	
 

	
PCA OF
  DENVER, INC. 

	
 

	
PCA OF
  NASHVILLE, INC. 

	
 

	
PETER G.
  KLACSMANN M.D., INC. 

	
 

	
REGIONAL
  PATHOLOGY CONSULTANTS, LLC 

	
 

	
ROCKY
  MOUNTAIN PATHOLOGY, LLC

	
 

	
SHARON G.
  DASPIT, M.D., INC.

	
 

	
SHOALS
  PATHOLOGY ASSOCIATES, INC.

	
 

	
SPECIALTY
  LABORATORIES, INC.

	
 

	
STRIGEN,
  INC. 

	
 

	
TID ACQUISITION CORP. 

	
 

	
 

	
 

	
By: 

	
 

	
 

	
 

	

	
 

	
 

	
          Name:

	
 

	
 

	
          Title:

B-14

	
 

	
 

	
 

	
 

	
ENTERIX INC.

	
 

	
HEMOCUE,
  INC.

	
 

	
 

	
 

	
By: 

	
 

	
 

	
 

	

	
 

	
                       Name: 

	
 

	
                       Title: 

	
 

	
 

	
 

	
QUEST
  DIAGNOSTICS INVESTMENTS INCORPORATED QUEST DIAGNOSTICS FINANCE INCORPORATED

	
 

	
 

	
 

	
By:

	
 

	
 

	
 

	

	
 

	
                       Name: 

	
 

	
                       Title: 

B-15

EXHIBIT C

FORM OF ADDITIONAL SUBSIDIARY GUARANTEE

                    FOR
VALUE RECEIVED, each of the Subsidiary Guarantors executing this additional
Subsidiary Guarantee (the “Additional Subsidiary Guarantors”), hereby fully and
unconditionally guarantees, jointly and severally, together with the existing
Subsidiary Guarantors (as such term is defined in the Indenture) of the Note,
to the Holder of the Note upon which this additional Subsidiary Guarantee is
endorsed (the “Note”) and to the Trustee on behalf of the Holder, the prompt
payment of the principal of (and premium, if any, on) and interest (including,
in case of default, interest on principal and, to the extent permitted by
applicable law, on overdue interest and including any additional interest
required to be paid according to the terms of the Notes) on the Note, when due
(whether at Stated Maturity, upon Redemption, upon acceleration, upon tender
for repayment at the option of the Company), according to the terms hereof and
the terms of the Indenture (the “Guarantor Obligations”). This Guarantee is a
guarantee of payment and not of collection and is a continuing guarantee and
shall apply to all Guarantor Obligations whenever arising. 

                    Obligations
Unconditional and Absolute. The obligations of the Additional Subsidiary
Guarantors hereunder are absolute and unconditional irrespective of the value,
genuineness, validity, regularity or enforceability of the Indenture or this
Note, to the fullest extent permitted by applicable law, irrespective of any
circumstance whatsoever which might otherwise constitute a legal or equitable
discharge or defense of a surety or guarantor. Each of the Additional
Subsidiary Guarantors agrees that this Guarantee may be enforced by the Holder
of this Note without the necessity at any time of proceeding against the
Company or any other Person (including a co-guarantor) or to pursue any other
remedy or enforce any other right. Each of the Subisidary Guarantors further
agrees that nothing contained herein shall prevent the Holder of this Note from
suing on this Note or the Indenture or from exercising any other rights
available under this Note and the Indenture, and the exercise of any of the
aforesaid rights and shall not constitute a discharge of any Additional
Subsidiary Guarantor’s obligations hereunder and under the Indenture; it being
the purpose and the intent of each Additional Subsidiary Guarantor that its
obligations under this Note and under the Indenture shall be absolute,
independent and unconditional under any and all circumstances. Neither any
Additional Subsidiary Guarantor’s obligations under this Subsidiary Guarantee
nor any remedy for the enforcement thereof shall be impaired, modified, changed
or released in any manner whatsoever by an impairment, modification, change,
release or limitation of the liability of the Company or by reason of the
bankruptcy or insolvency of the Company. Each Additional Subsidiary Guarantor
waives any and all notice of the creation, renewal, extension or accrual of any
of the Guarantor Obligations or acceptance of this Subsidiary Guarantee. The
Guarantor Obligations, and any of them, shall conclusively be deemed to have
been created, contracted or incurred, or renewed, extended, amended or waived,
in reliance upon this Guarantee. 

                    Subrogation.
Each of the Additional Subsidiary Guarantors shall be subrogated to all rights
of the Holder of the Note against the Company in respect of any amounts paid by
such Additional Subsidiary Guarantor on account of the Note or the Indenture; provided, however, that such Additional
Subsidiary Guarantor shall not be entitled to enforce or to receive any
payments arising out of, or based upon, such right of subrogation until the
principal of (or premium, if any, on) and interest on all Notes of this series
shall have been indefeasibly paid in full. 

C-1

                    Modifications.
Each Subsidiary Guarantor agrees that (a) the time or place of payment of the
Guarantor Obligations may be changed or extended, in whole or in part, to a
time certain or otherwise, and may be renewed or accelerated, in whole or in
part; (b) the Company and any other party liable for payment under the
Indenture or under the Note may be granted indulgences generally; (c) any of
the provisions of this Note or the Indenture may be modified, amended or
waived; and (d) any party (including any Subsidiary Guarantor) liable for the
payment under this Note or under the Indenture may be granted indulgences or be
released; all without notice to or further assent by such Subsidiary Guarantor,
which shall remain bound thereon, notwithstanding any such exchange,
compromise, surrender, extension, renewal, acceleration, modification,
indulgence or release.

                    Waiver
of Rights. Each of the Additional Subsidiary Guarantors hereby waives to
the fullest extent permitted by law: (a) notice of acceptance of this Guarantee
by the Holder of this Note; (b) presentment and demand for payment or
performance of any of the Guarantor Obligations; (c) protest and notice of
dishonor or default with respect to the Guarantor Obligations; (d) all other
notices to which such Additional Subsidiary Guarantor might otherwise be
entitled. 

                    Reinstatement.
The obligations of the Additional Subsidiary Guarantors under this Note and
under Article Sixteen shall be automatically reinstated if and to the extent
that for any reason any payment by or on behalf of any Person in respect of the
Guarantor Obligations is rescinded or must otherwise be restored by any Holder
of the Notes of this series, whether as a result of any proceedings in
bankruptcy or reorganization or otherwise.

                    Remedies.
Each of the Additional Subsidiary Guarantors further agrees, to the fullest
extent that it may lawfully do so, that as between each such Additional
Subsidiary Guarantor, on the one hand, and the Holder and the Trustee, on the
other hand, the maturity of the obligations guaranteed hereby may be
accelerated as provided in Article Five of the Indenture for the purposes of
this guarantee, notwithstanding any stay, injunction or other prohibition
extant under any applicable bankruptcy law preventing such acceleration in
respect of the obligations guaranteed hereby. 

                    Rights
of Contribution. The Additional Guarantors, in connection with payments
made hereunder, shall have contribution rights against the other Subsidiary
Guarantors as permitted under applicable law. Such contribution rights shall be
subordinate and subject in right of payment to the obligations of the
Subsidiary Guarantors under this Note and no Additional Subsidiary Guarantor
shall exercise such rights of contribution until all Guarantor Obligations have
been paid in full.

                    Limitation
of Guaranty. Notwithstanding any provision to the contrary contained herein
or in the Indenture, to the extent the obligations of any Additional Subsidiary
Guarantor shall be adjudicated to be invalid or unenforceable for any reason
(including, without limitation, because of any applicable state or federal law
relating to fraudulent conveyances or transfers) then the obligations of the
Additional Subsidiary Guarantors hereunder shall be limited to the maximum
amount that is permissible under applicable law (whether federal or state or
otherwise and including, without limitation, the Bankruptcy Code).

                    Release
of Guarantors. Each of the Additional Subsidiary Guarantors hereby
covenants that its Subsidiary Guarantee will not be discharged except by
complete performance of its obligations contained in the Note, this Subsidiary
Guarantee and pursuant to the Indenture; provided, however,
that if (a) an Additional Subsidiary Guarantor does not guarantee any
Indebtedness of the Company the amount of which, when added together with any
other outstanding Indebtedness of the Company guaranteed by its Subsidiaries
that are not Subsidiary Guarantors, would exceed $50 million in the aggregate,
excluding the Notes of this series, and all outstanding Indebtedness of such
Subsidiary Guarantor would have been

C-2

permitted to be incurred
pursuant to Section 1011 of the Indenture measured at the time of the release
and discharge as described in this paragraph, (b) the Notes of this series are
defeased and discharged pursuant to Article Fourteen of the Indenture, or (c)
all or substantially all of the assets of such Additional Subsidiary Guarantor
or all of the capital stock of such Additional Subsidiary Guarantor is sold
(including by issuance, merger, consolidation or otherwise) by the Company or
any of its Subsidiaries, then in each case of (a), (b) or (c) above, such
Subsidiary Guarantor or the corporation acquiring such assets (in the event of
a sale or other disposition of all or substantially all of the assets or
capital stock of such Subsidiary Guarantor) shall be automatically and without any
further action on the part of any party to the Indenture, and upon notice to
the Trustee, be fully released and discharged from all its liabilities and
obligations under or in respect of the Indenture and this Subsidiary Guarantee
of the Note, and promptly upon the request of the Company and at the expense of
the Company, the Trustee shall execute such documents and take such other
action as is reasonably requested by the Company to evidence the release and
discharge of such Guarantor from all such liabilities and obligations and
shall, if applicable, certify to the Company that such Additional Subsidiary
Guarantor has no liabilities or obligations resulting from a demand on such
Additional Subsidiary Guarantor’s Guarantee. 

                    Defined
Terms. All terms used in this Note, which are defined in the Indenture and
are not otherwise defined herein, shall have the meanings assigned to them in
the Indenture.

                    Governing
Law. This Subsidiary Guarantee shall be governed by and
construed in accordance with the law of the State of New York.                      

                    This
Subsidiary Guarantee shall be governed by and construed in accordance with the
laws of the State of New York, without regard to principles of conflicts of
laws.

                    Subject
to the next following paragraph, each Additional Subsidiary Guarantor hereby
certifies and warrants that all acts, conditions and things required to be done
and performed and to have happened precedent to the creation and issuance of
this Subsidiary Guarantee and to constitute the same valid obligation of each
Additional Subsidiary Guarantor have been done and performed and have happened
in due compliance with all applicable laws. 

(Remainder of page intentionally left blank.)

C-3

                    This
Subsidiary Guarantee shall not be valid or become obligatory for any purpose
until the certificate of authentication on the Note upon which this Subsidiary
Guarantee is endorsed has been signed by the Trustee under the Indenture
referred to in this Note. 

	
 

	
 

	
 

	
 

	
Dated: 

	
         [ADDITIONAL
  SUBSIDIARY GUARANTOR(S)]

	
 

	

	
 

	
 

	
 

	
Attest:

	
By:

	

	
 

	
Name:

	

	
Title: 

	
Name:

	
 

	
 

	
Title:

	
 

	
 

C-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00125-of-00352.parquet"}]]